NCT06129734
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant treatment 1 / 2 not_yet_recruiting NCT03904134
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) No drug interventions treatment Not Available active_not_recruiting NCT05144334
A Study of BTX-1188 in Subjects With Advanced Malignancies No drug interventions treatment 1 terminated NCT03719534
Haplo HCT vs Haplo-cord HCT for Patients With AML No drug interventions treatment 3 completed NCT01686334
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission No drug interventions treatment 2 active_not_recruiting NCT05829434
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS treatment 2 withdrawn NCT03128034
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia treatment 1 / 2 suspended NCT03245424
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation Not Available Not Available approved_for_marketing NCT03662724
Venetoclax Registry Not Available Not Available recruiting NCT02508324
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia No drug interventions treatment 2 terminated NCT05541224
A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers No drug interventions Not Available Not Available completed NCT03483324
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation No drug interventions treatment 1 completed NCT04632316
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia treatment 1 / 2 unknown_status NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide treatment 1 recruiting NCT03298516
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy treatment 1 completed NCT03337516
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers other Not Available unknown_status NCT05442216
Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents treatment 2 recruiting NCT00766116
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT00089596
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers No drug interventions treatment 1 / 2 completed NCT00640796
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors treatment 1 completed NCT00037596
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia treatment 2 completed NCT04051996
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia treatment 2 terminated NCT04167696
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 treatment 1 recruiting NCT06575296
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant treatment 1 not_yet_recruiting NCT06501196
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT03810196
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT No drug interventions treatment Not Available recruiting NCT00187096
Natural Killer (NK) Cell Transplantation for AML treatment Not Available completed NCT01015196
Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation treatment 2 / 3 completed NCT00797758
Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia No drug interventions treatment 2 completed NCT04095858
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) treatment 3 terminated NCT02807558
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT06347458
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children treatment 1 not_yet_recruiting NCT04361058
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide treatment 1 withdrawn NCT00565058
Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) treatment 2 completed NCT02863458
DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US No drug interventions Not Available Not Available withdrawn NCT03600558
Efficacy of FLAG Regimen for the Treatment of Patients With AML No drug interventions Not Available Not Available unknown_status NCT06017258
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT01311258
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome No drug interventions Not Available Not Available recruiting NCT03709758
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML treatment 1 recruiting NCT05801835
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection treatment Not Available recruiting NCT06440135
Ziftomenib Maintenance Post Allo-HCT treatment 1 not_yet_recruiting NCT03127735
BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) No drug interventions treatment 1 completed NCT02722135
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed treatment 1 withdrawn NCT02485535
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant treatment 1 completed NCT03850535
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission treatment 1 / 2 terminated NCT02084563
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms basic_science 2 completed NCT02674763
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia treatment 1 completed NCT05968963
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation No drug interventions supportive_care Not Available recruiting NCT06420063
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML No drug interventions treatment 1 / 2 recruiting NCT05447663
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant treatment 1 / 2 terminated NCT04265963
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 recruiting NCT05016063
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia treatment 0 unknown_status NCT01334086
Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy prevention 2 completed NCT02926586
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML treatment 4 unknown_status NCT02899286
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 unknown_status NCT01280786
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 unknown_status NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib treatment 2 not_yet_recruiting NCT03055286
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients treatment 1 / 2 unknown_status NCT00859586
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available completed NCT05961839
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT03315039
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT02646839
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children No drug interventions treatment 2 enrolling_by_invitation NCT04288739
Immunophenotyping and Xist Gene in AML No drug interventions Not Available Not Available unknown_status NCT04326439
AflacLL1901 (CHOA-AML) treatment 2 terminated NCT05275439
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML treatment 1 recruiting NCT05189639
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT06349239
Oral Azacitidine Maintenance Post-CPX 351 No drug interventions Not Available Not Available recruiting NCT02343939
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) treatment 1 / 2 terminated NCT05657639
CAV Regimen for R/R AML No drug interventions treatment 2 recruiting NCT05010122
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04913922
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML treatment 2 recruiting NCT02323022
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) No drug interventions treatment 3 completed NCT04613622
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia Not Available Not Available recruiting NCT00081822
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia treatment 1 completed NCT04169022
AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells No drug interventions screening Not Available completed NCT04351022
CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT02046122
Adoptive Transfer of Haplo-identical DLI for AML and MDS treatment 1 / 2 completed NCT04272125
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 recruiting NCT02203825
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands No drug interventions treatment 1 completed NCT00967525
Intraosseous Infusion of Unrelated Cord Blood Grafts No drug interventions treatment Not Available terminated NCT02560025
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML treatment 2 completed NCT01075425
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT00742625
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 1 / 2 completed NCT01315925
Pre-hospital Risk Factors for Invasive Fungal Infection No drug interventions Not Available Not Available unknown_status NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT00602225
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 completed NCT03286530
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML treatment 2 recruiting NCT02103530
Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT No drug interventions diagnostic Not Available completed NCT01587430
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia treatment 4 unknown_status NCT04100330
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 withdrawn NCT05115630
Off-the-shelf NK Cells + SCT for Myeloid Malignancies treatment 1 / 2 recruiting NCT05079230
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia treatment 3 terminated NCT00316030
Study of Bexarotene in Patients With Acute Myeloid Leukemia treatment 1 completed NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies treatment 1 / 2 recruiting NCT01188330
Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival No drug interventions supportive_care Not Available unknown_status NCT00795548
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation treatment 2 completed NCT04128748
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT05444348
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT) No drug interventions supportive_care Not Available recruiting NCT03435848
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy treatment 2 completed NCT03066648
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS treatment 1 completed NCT04692948
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia No drug interventions treatment Not Available unknown_status NCT03441048
Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia treatment 1 completed NCT03483948
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia treatment 1 terminated NCT02859948
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 unknown_status NCT02848248
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT01834248
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 completed NCT04986657
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS No drug interventions diagnostic Not Available recruiting NCT05361057
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients treatment 2 unknown_status NCT02464657
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT06458257
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT04272957
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms No drug interventions treatment 1 unknown_status NCT03747757
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue No drug interventions supportive_care 2 active_not_recruiting NCT04887857
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) treatment 1 completed NCT02286726
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia treatment 2 completed NCT05197426
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission treatment 2 recruiting NCT05161026
Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry No drug interventions other Not Available not_yet_recruiting NCT05015426
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT No drug interventions treatment 1 recruiting NCT03881826
Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia No drug interventions basic_science Not Available completed NCT04158726
Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia No drug interventions health_services_research Not Available completed NCT05188326
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients treatment 3 completed NCT04023526
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy treatment 2 active_not_recruiting NCT01180426
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia treatment 2 unknown_status NCT00831766
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT02099266
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment No drug interventions treatment Not Available completed NCT04062266
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission treatment 2 recruiting NCT06439966
Expanded Access to ABBV-787 No drug interventions Not Available Not Available available NCT03526666
Ascorbic Acid Levels in MDS, AML, and CMML Patients No drug interventions Not Available Not Available completed NCT03720366
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients treatment 1 completed NCT02229266
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML treatment 2 terminated NCT00186966
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia treatment 3 completed NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies treatment 1 recruiting NCT05066165
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia No drug interventions treatment 1 / 2 terminated NCT05014165
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood No drug interventions Not Available Not Available recruiting NCT03233074
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors No drug interventions Not Available Not Available terminated NCT00861874
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT03092674
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 / 3 active_not_recruiting NCT03222674
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT06475820
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis treatment 2 / 3 active_not_recruiting NCT01440920
A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients No drug interventions treatment 1 completed NCT03484520
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 terminated NCT02059720
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 No drug interventions treatment 3 unknown_status NCT00954720
Observational Study of Iron Overload in Stem Cell Transplantation No drug interventions Not Available Not Available completed NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT02056782
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia treatment 1 completed NCT01943682
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma No drug interventions treatment 1 completed NCT03560882
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies treatment 1 active_not_recruiting NCT00079482
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) treatment 2 completed NCT01961882
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia No drug interventions treatment 2 completed NCT04336982
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia treatment 1 terminated NCT00764231
A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) No drug interventions treatment 2 completed NCT04906031
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations treatment 2 unknown_status NCT06362031
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review No drug interventions Not Available Not Available withdrawn NCT03422731
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy diagnostic 0 recruiting NCT06024031
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy treatment 2 not_yet_recruiting NCT00926731
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) treatment 1 completed NCT01141673
Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT03397173
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid treatment 2 completed NCT00964873
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia treatment 1 completed NCT03395873
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy treatment 1 terminated NCT01700673
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS treatment 2 completed NCT00866073
Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia treatment 2 completed NCT01256073
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia treatment 1 completed NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 1 recruiting NCT00279773
Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia treatment 1 terminated NCT03235973
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes treatment 1 unknown_status NCT02034227
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia treatment 1 / 2 terminated NCT04885127
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia No drug interventions supportive_care Not Available recruiting NCT06463327
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML treatment 1 not_yet_recruiting NCT04107727
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) treatment 2 unknown_status NCT03379727
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. treatment 3 completed NCT01048827
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen treatment 1 completed NCT03045627
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients treatment 2 unknown_status NCT03897127
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics treatment 3 recruiting NCT03878927
CPX-351+GO in Subjects 55 Years Old, or Older, With AML treatment 1 terminated NCT02949427
The Oronasal Microbiota in Pediatric Oncology Patients No drug interventions Not Available Not Available completed NCT02109627
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML treatment 1 terminated NCT06345027
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) No drug interventions treatment 1 not_yet_recruiting NCT02530476
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia treatment 1 / 2 completed NCT01721876
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) treatment 3 completed NCT00538876
Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML treatment 1 completed NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression treatment 3 active_not_recruiting NCT04811560
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia treatment 1 / 2 recruiting NCT04311060
Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. No drug interventions Not Available Not Available not_yet_recruiting NCT03347994
Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 withdrawn NCT05024994
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers treatment 2 active_not_recruiting NCT03568994
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) treatment 0 active_not_recruiting NCT06232694
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML treatment Not Available recruiting NCT05654194
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML treatment 3 recruiting NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy treatment 1 recruiting NCT03372291
Psychological Intervention Mobile App for Patients With AML No drug interventions supportive_care Not Available completed NCT04477291
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS treatment 1 active_not_recruiting NCT02306291
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML treatment 1 / 2 completed NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT05063591
Removing Transfusion Dependence as a Barrier to Hospice Enrollment No drug interventions supportive_care Not Available active_not_recruiting NCT02610062
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) No drug interventions treatment 1 terminated NCT02684162
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant treatment 2 active_not_recruiting NCT01883362
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML prevention 2 completed NCT03488862
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients No drug interventions Not Available Not Available completed NCT02756962
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance treatment 2 active_not_recruiting NCT01130662
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia treatment 1 completed NCT06497062
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia treatment 2 not_yet_recruiting NCT04342962
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia treatment 2 recruiting NCT01398462
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients No drug interventions treatment 1 completed NCT06220162
VAC Regimen for AML Patients Who Failed to Response to VA Regimen treatment 2 recruiting NCT04953780
2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML treatment 1 active_not_recruiting NCT03824080
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes treatment 2 completed NCT04977180
Cardioprotection in AML No drug interventions prevention 2 recruiting NCT05424380
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS No drug interventions treatment 1 active_not_recruiting NCT04155580
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) treatment 1 terminated NCT02835729
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT00373529
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) treatment 2 completed NCT03552029
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) treatment 1 terminated NCT02842229
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms No drug interventions Not Available Not Available completed NCT01902329
A Safety Study of SGN-CD33A in AML Patients treatment 1 completed NCT02392429
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia diagnostic 2 active_not_recruiting NCT02348489
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction treatment 3 completed NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 withdrawn NCT02096289
Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT06030089
Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven basic_science Not Available recruiting NCT05659992
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia treatment 1 recruiting NCT02831192
Microtransplantation in Older Patients With Acute Myeloid Leukemia No drug interventions treatment 2 completed NCT01819792
Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia No drug interventions other 4 completed NCT02588092
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) treatment 1 terminated NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers treatment 1 active_not_recruiting NCT03300492
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS No drug interventions treatment 1 / 2 recruiting NCT03806192
Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid Leukemia No drug interventions supportive_care Not Available terminated NCT04708444
Prognostic Value of CD318 in AML at Assiut University Hospital. No drug interventions Not Available Not Available unknown_status NCT00469144
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome treatment 3 completed NCT03063944
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy treatment 1 completed NCT06287944
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome treatment 1 not_yet_recruiting NCT06458244
The Efficacy of Allo-HSCT in ND HR-CBF-AML Not Available Not Available not_yet_recruiting NCT00358644
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) treatment 2 completed NCT06559644
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia No drug interventions treatment 0 not_yet_recruiting NCT01542944
TevaGastrim for Stem Cell Mobilization Sibling Donors treatment 2 completed NCT04755244
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) treatment 1 / 2 active_not_recruiting NCT01488344
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) treatment 1 / 2 unknown_status NCT04055844
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS treatment 2 completed NCT05834244
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) treatment 1 recruiting NCT05470140
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) treatment 1 active_not_recruiting NCT05744440
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT treatment 0 recruiting NCT06424340
MB-dNPM1-TCR.1 in Relapsed/Refractory AML No drug interventions treatment 1 / 2 recruiting NCT04254640
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML treatment 2 unknown_status NCT02841540
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes treatment 1 terminated NCT00908167
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies treatment 1 completed NCT04087967
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients treatment 3 unknown_status NCT03335267
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia No drug interventions treatment 2 completed NCT04097301
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma No drug interventions treatment 1 / 2 terminated NCT01398501
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant treatment 1 completed NCT04128501
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting treatment 2 recruiting NCT05580601
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 recruiting NCT01068301
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation treatment 1 completed NCT04742101
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT04969601
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings prevention 1 / 2 completed NCT04678401
IS-free Treg HaploHCT treatment 1 recruiting NCT01191801
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML treatment 3 completed NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD treatment 1 / 2 withdrawn NCT02856204
Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT05512104
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression No drug interventions Not Available Not Available unknown_status NCT02566304
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04658004
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia No drug interventions treatment 0 not_yet_recruiting NCT06234904
Study of IBR733 Cell Injection in Acute Myeloid Leukemia No drug interventions treatment 1 not_yet_recruiting NCT03150004
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) treatment 2 recruiting NCT00986804
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant treatment 1 completed NCT05139004
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT01608204
Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation No drug interventions Not Available Not Available completed NCT05893472
A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. treatment 1 / 2 recruiting NCT03012672
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm treatment 2 completed NCT03790072
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) treatment 1 completed NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors treatment 1 / 2 recruiting NCT04714372
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT02432872
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years treatment Not Available unknown_status NCT00867672
Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia treatment 2 completed NCT05983172
Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia No drug interventions Not Available Not Available enrolling_by_invitation NCT06382168
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT02782468
A Study of Pevonedistat in Adult East Asian Participants treatment 1 completed NCT06510868
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy No drug interventions Not Available Not Available not_yet_recruiting NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT01643668
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation treatment 2 completed NCT03337568
Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission No drug interventions Not Available Not Available unknown_status NCT02502968
BL-8040 Addition to Consolidation Therapy in AML Patients treatment 2 unknown_status NCT04021368
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome treatment 1 active_not_recruiting NCT00909168
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) treatment 2 / 3 completed NCT02440568
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients treatment 1 / 2 terminated NCT01565668
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 completed NCT05428969
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies treatment 1 / 2 recruiting NCT06073769
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia Not Available Not Available recruiting NCT05456269
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS treatment 1 withdrawn NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection No drug interventions Not Available Not Available recruiting NCT05335369
A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists No drug interventions supportive_care Not Available recruiting NCT02975869
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions supportive_care Not Available active_not_recruiting NCT04827069
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML) No drug interventions treatment 1 unknown_status NCT03941769
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II supportive_care 1 / 2 completed NCT01463046
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome treatment 1 completed NCT00819546
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS treatment 1 active_not_recruiting NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) treatment 2 completed NCT03839446
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy treatment 2 active_not_recruiting NCT02473146
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 treatment 2 / 3 completed NCT02782546
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation treatment 2 recruiting NCT02960646
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03493646
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 treatment 2 completed NCT03735446
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial treatment 1 terminated NCT03036046
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia treatment 1 / 2 withdrawn NCT04581512
Study to Evaluate the Safety and Tolerability of EP0042 treatment 1 / 2 recruiting NCT01910012
PH 2 ADI-PEG 20 Acute Myeloid Leukemia treatment 2 completed NCT05312112
Real World Outcomes Using Novel Agents for AML in the UK Not Available Not Available recruiting NCT03173612
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia treatment Not Available recruiting NCT02842112
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT03499912
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy No drug interventions Not Available Not Available unknown_status NCT03913312
Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML No drug interventions treatment 1 / 2 unknown_status NCT03450512
Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy No drug interventions Not Available Not Available recruiting NCT03515512
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation treatment 1 completed NCT02483312
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) No drug interventions treatment 1 recruiting NCT00226512
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning treatment 3 withdrawn NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia No drug interventions supportive_care 2 terminated NCT06536010
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML treatment Not Available recruiting NCT04849910
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS treatment 1 / 2 recruiting NCT04905810
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure treatment 2 recruiting NCT04392310
Outcomes of Acute Myeloid Leukemia Patients No drug interventions Not Available Not Available unknown_status NCT02400281
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients treatment 1 / 2 completed NCT04267081
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening treatment 2 completed NCT04008381
Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia No drug interventions treatment 1 unknown_status NCT04657081
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) treatment 1 / 2 active_not_recruiting NCT00651781
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia treatment 1 / 2 completed NCT00866281
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia treatment 1 / 2 terminated NCT01371981
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 active_not_recruiting NCT06543381
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant treatment 1 recruiting NCT02190695
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS treatment 2 completed NCT03603795
Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy treatment 2 unknown_status NCT02683395
A Study of PLX51107 in Advanced Malignancies treatment 1 terminated NCT04373395
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML) No drug interventions treatment Not Available unknown_status NCT02159495
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm treatment 1 active_not_recruiting NCT01838395
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients treatment 2 completed NCT02984995
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation treatment 2 completed NCT02115295
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia treatment 2 recruiting NCT00224614
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia No drug interventions diagnostic 3 unknown_status NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT04296214
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Not Available Not Available withdrawn NCT05858814
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT No drug interventions prevention 1 / 2 recruiting NCT05766514
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction treatment 2 not_yet_recruiting NCT05636514
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS treatment 1 recruiting NCT02981914
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation treatment 0 completed NCT03286114
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab treatment 1 terminated NCT00469014
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia treatment 2 completed NCT02995655
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia treatment 1 completed NCT01702155
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia No drug interventions treatment 1 / 2 completed NCT00790855
Bendamustine in Acute Leukemia and MDS treatment 1 / 2 terminated NCT02419755
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies treatment 2 terminated NCT03918655
MIF Involvement in AML No drug interventions Not Available Not Available active_not_recruiting NCT05682755
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT treatment 1 / 2 recruiting NCT04988555
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation treatment 1 / 2 recruiting NCT03633955
Pilot Imaging Study of Leukemia No drug interventions diagnostic 1 recruiting NCT03737955
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia treatment 2 recruiting NCT03555955
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 treatment 1 completed NCT06232655
Cladribine Venetoclax in Monocytic AML treatment 2 recruiting NCT01161550
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML treatment 1 completed NCT01684150
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving treatment 1 completed NCT02728050
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 completed NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) No drug interventions treatment 1 / 2 suspended NCT01352650
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) treatment 1 completed NCT00809250
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation No drug interventions treatment 1 completed NCT04460950
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms No drug interventions Not Available Not Available recruiting NCT02774850
Home Away From Home - Medical Outcomes No drug interventions Not Available Not Available completed NCT02029950
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 completed NCT02328950
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome Not Available Not Available unknown_status NCT01056523
Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia treatment 1 / 2 completed NCT00687323
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) treatment 2 completed NCT01701323
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 terminated NCT02928523
PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients treatment 1 / 2 completed NCT05628623
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment treatment 2 not_yet_recruiting NCT02758223
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT No drug interventions treatment 1 / 2 completed NCT02920008
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia treatment 3 completed NCT01041508
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. treatment 1 completed NCT05991908
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies treatment 3 recruiting NCT04069208
IA14 Induction in Young Acute Myeloid Leukemia treatment 2 unknown_status NCT02416908
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 completed NCT03151408
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia treatment 3 terminated NCT02024308
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy treatment 4 unknown_status NCT00885508
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q treatment 2 unknown_status NCT02544438
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT04337138
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World Not Available Not Available completed NCT01461538
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies treatment 2 completed NCT06469138
A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects treatment 1 completed NCT01546038
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00931138
Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 treatment 3 completed NCT02405338
DC Vaccination for Post-remission Therapy in AML No drug interventions treatment 1 / 2 completed NCT03932643
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant treatment 1 active_not_recruiting NCT03718143
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis treatment 2 terminated NCT00924443
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable treatment 2 completed NCT04676243
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML treatment 3 withdrawn NCT06537843
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia treatment 2 recruiting NCT04262843
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia treatment 2 recruiting NCT00880243
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) treatment 3 completed NCT01141543
Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection Not Available Not Available completed NCT03977103
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT No drug interventions treatment 2 unknown_status NCT03063203
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia treatment 2 terminated NCT00159003
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel No drug interventions Not Available Not Available completed NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT06006403
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm treatment 1 / 2 recruiting NCT05732103
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes No drug interventions treatment 1 / 2 recruiting NCT05212103
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 No drug interventions Not Available Not Available enrolling_by_invitation NCT02474290
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML treatment 2 / 3 completed NCT06285890
Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia treatment 1 recruiting NCT04836390
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant treatment 2 enrolling_by_invitation NCT00093990
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 3 completed NCT02864290
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) No drug interventions treatment 1 terminated NCT03744390
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) screening 2 recruiting NCT05774990
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment No drug interventions Not Available Not Available active_not_recruiting NCT04946890
A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 not_yet_recruiting NCT00522990
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias treatment 1 / 2 terminated NCT01720264
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant treatment 2 completed NCT04086264
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT05330364
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia treatment 2 unknown_status NCT03912064
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT treatment 1 active_not_recruiting NCT03603964
Guadecitabine Extension Study treatment 2 terminated NCT00300664
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Not Available 2 / 3 completed NCT04471064
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT02310321
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. treatment 1 / 2 active_not_recruiting NCT02632721
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT02413021
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens treatment 1 unknown_status NCT00620321
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 completed NCT03433521
Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT00559221
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML No drug interventions treatment 2 unknown_status NCT03326921
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant treatment 1 suspended NCT02461121
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk treatment 3 completed NCT02312102
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation treatment 1 active_not_recruiting NCT03349502
MG4101 for Refractory or Relapsed AML treatment 2 completed NCT05218902
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available completed NCT03027102
Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia No drug interventions treatment 1 active_not_recruiting NCT01534702
Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML treatment 1 / 2 unknown_status NCT02997202
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) treatment 3 completed NCT05168202
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 1 active_not_recruiting NCT04033302
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies No drug interventions treatment 1 / 2 unknown_status NCT04168502
Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML treatment 3 recruiting NCT00583102
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML treatment 1 / 2 terminated NCT02641002
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 terminated NCT05246384
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia No drug interventions treatment 1 / 2 withdrawn NCT05342584
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS treatment 1 recruiting NCT04884984
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) No drug interventions treatment 1 / 2 recruiting NCT00273884
Amonafide in Combination With Cytarabine in Secondary AML treatment 2 completed NCT03451084
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia treatment 2 completed NCT03298984
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). treatment 1 completed NCT02326584
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML treatment 1 completed NCT03795779
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies treatment 0 unknown_status NCT03915379
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT05654779
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT01843179
Sulindac for Patients With AML treatment 2 withdrawn NCT01606579
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies treatment 1 / 2 completed NCT04092179
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers treatment 1 / 2 terminated NCT06138587
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation No drug interventions treatment 1 recruiting NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) treatment 2 recruiting NCT06419634
Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT06492707
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial No drug interventions treatment 1 recruiting NCT02275533
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial treatment 2 active_not_recruiting NCT03041688
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03154827
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) treatment 1 / 2 terminated NCT03530683
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma treatment 1 terminated NCT03814005
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems other 1 completed NCT03850574
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers treatment 2 enrolling_by_invitation NCT04188405
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia treatment 2 active_not_recruiting NCT04256317
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML treatment 2 / 3 recruiting NCT04282668
A Study of TAS1440 With ATRA in Subjects With r/r AML treatment 1 active_not_recruiting NCT04774393
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT05101551
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy treatment 1 recruiting NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) treatment 2 recruiting NCT05554406
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) treatment 2 recruiting NCT06571825
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR treatment 4 recruiting NCT06572982
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients treatment Not Available not_yet_recruiting NCT01139970
Veliparib and Temozolomide in Treating Patients With Acute Leukemia treatment 1 active_not_recruiting NCT01757535
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission treatment 3 completed NCT02386800
CINC424A2X01B Rollover Protocol treatment 4 recruiting NCT03306264
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML treatment 3 completed NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies treatment 2 recruiting NCT04314401
National Cancer Institute "Cancer Moonshot Biobank" No drug interventions Not Available Not Available recruiting NCT04623216
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. treatment 1 / 2 active_not_recruiting NCT04746235
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia treatment 2 recruiting NCT05272293
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML No drug interventions treatment 1 / 2 recruiting NCT05334693
Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML treatment 1 / 2 recruiting NCT05583552
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy treatment 2 recruiting NCT05955261
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia treatment 2 recruiting NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis treatment 2 recruiting NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT06058741
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy No drug interventions Not Available Not Available recruiting NCT06580106
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML No drug interventions Not Available Not Available not_yet_recruiting NCT06191978
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) treatment 1 recruiting NCT06378437
A Study of GLB-001 in Patients With Myeloid Malignancies No drug interventions treatment 1 recruiting NCT06529731
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation treatment 2 recruiting NCT02270463
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission treatment 1 / 2 terminated NCT03173248
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation treatment 3 active_not_recruiting NCT03187288
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS treatment 1 completed NCT03760523
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 terminated NCT03839771
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy treatment 3 recruiting NCT03970096
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) treatment 2 recruiting NCT04150029
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy treatment 2 active_not_recruiting NCT04284787
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT04380441
Quality of Life Model for Older Patients With AML No drug interventions Not Available Not Available active_not_recruiting NCT04435691
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT04951778
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes No drug interventions treatment 1 recruiting NCT05396859
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia treatment 1 recruiting NCT05457556
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome treatment 3 recruiting NCT05506956
Post-transplant Flotetuzumab for AML treatment 1 completed NCT05521087
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias treatment 1 withdrawn NCT05569512
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML treatment 1 terminated NCT05945849
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML No drug interventions treatment 1 recruiting NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases treatment 2 recruiting NCT06221683
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML treatment 2 recruiting NCT06399640
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia treatment 1 recruiting NCT06470841
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML treatment 2 not_yet_recruiting NCT06557421
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients treatment 2 not_yet_recruiting NCT06551584
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT No drug interventions treatment 1 not_yet_recruiting NCT02390635
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia diagnostic 1 recruiting NCT03927261
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS treatment 1 active_not_recruiting NCT04214249
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia treatment 2 recruiting NCT04263181
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration No drug interventions Not Available Not Available recruiting NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations treatment 3 active_not_recruiting NCT04659616
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia treatment 1 recruiting NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study No drug interventions screening 1 / 2 recruiting NCT04802161
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes treatment 2 suspended NCT04905407
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML treatment 2 active_not_recruiting NCT05326516
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia treatment 1 completed NCT05453903
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies treatment 1 recruiting NCT05587049
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia No drug interventions Not Available Not Available recruiting NCT05662956
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients treatment 1 / 2 recruiting NCT05984199
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant No drug interventions treatment 1 / 2 recruiting NCT06066242
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy No drug interventions treatment Not Available recruiting NCT06384261
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy treatment 2 recruiting NCT02521493
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome treatment 3 active_not_recruiting NCT02668653
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) treatment 3 completed NCT04167917
NTX-301 in MDS/AML No drug interventions treatment 1 recruiting NCT04511130
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant treatment 2 active_not_recruiting NCT05028751
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 terminated NCT05364762
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants prevention 2 recruiting NCT05622591
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML No drug interventions treatment 1 withdrawn NCT06068868
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) No drug interventions treatment 1 recruiting NCT06445907
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia treatment 1 not_yet_recruiting NCT06456463
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy treatment 2 not_yet_recruiting NCT02494167
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) No drug interventions treatment 1 recruiting NCT03318016
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 terminated NCT03573024
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia treatment 2 recruiting NCT03616470
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia treatment 3 terminated NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT03701308
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy treatment 2 / 3 suspended NCT03813186
Effect of Food on Blood Levels of ASTX727 basic_science 1 completed NCT03843528
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation treatment 1 recruiting NCT03844815
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03953898
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation treatment 2 active_not_recruiting NCT04013685
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT04637009
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms No drug interventions treatment 1 terminated NCT04953897
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment treatment 1 recruiting NCT04953910
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment treatment 1 recruiting NCT04964505
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT05360160
A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) treatment 1 / 2 recruiting NCT05413018
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission treatment 2 recruiting NCT05428176
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors No drug interventions supportive_care Not Available recruiting NCT05748197
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT06113289
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia treatment 1 / 2 suspended NCT06535113
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT06279572
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy No drug interventions Not Available Not Available recruiting NCT06297551
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) No drug interventions Not Available Not Available recruiting NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT treatment 2 recruiting NCT06514261
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML treatment 1 not_yet_recruiting NCT03121014
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes treatment 2 active_not_recruiting NCT03289910
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia treatment 2 active_not_recruiting NCT03439371
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia No drug interventions treatment Not Available recruiting NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies treatment 1 / 2 recruiting NCT04150887
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT04708054
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS treatment 2 recruiting NCT05455294
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms treatment 1 active_not_recruiting NCT05744739
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 active_not_recruiting NCT06111612
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement No drug interventions Not Available Not Available recruiting NCT06191263
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML treatment 2 recruiting NCT06357182
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia treatment 1 recruiting NCT06389292
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia treatment 3 recruiting NCT06448013
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia treatment 1 not_yet_recruiting NCT06483906
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. treatment 2 recruiting NCT06511882
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD treatment 2 recruiting NCT06513273
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) No drug interventions Not Available Not Available not_yet_recruiting NCT06504459
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML treatment 2 not_yet_recruiting NCT03268954
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) treatment 3 active_not_recruiting NCT04227847
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies treatment 1 recruiting NCT04609826
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 active_not_recruiting NCT06508489
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies treatment 1 / 2 recruiting NCT05933070
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML No drug interventions treatment 1 terminated NCT06034470
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms treatment 1 recruiting NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS treatment 1 recruiting NCT03383575
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome treatment 2 recruiting NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT03728335
Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant treatment 1 recruiting NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial treatment 3 active_not_recruiting NCT03862157
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT04047641
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04151706
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML treatment 2 completed NCT04835519
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 completed NCT04968015
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission treatment 2 active_not_recruiting NCT05038644
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia No drug interventions treatment 1 active_not_recruiting NCT05219266
Managed Access Programs for PKC412, Midostaurin Not Available Not Available no_longer_available NCT05358808
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) treatment 2 recruiting NCT05458258
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT05558124
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML treatment 1 recruiting NCT05659732
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer No drug interventions treatment 1 recruiting NCT05772559
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies No drug interventions Not Available Not Available recruiting NCT05796570
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies treatment 2 recruiting NCT06477549
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT treatment 2 recruiting NCT06021600
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine treatment 1 recruiting NCT06463639
FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT05317494
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece No drug interventions Not Available Not Available recruiting NCT05554419
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) treatment 2 not_yet_recruiting NCT05565105
CD34+ Transplants for Leukemia and Lymphoma treatment 2 not_yet_recruiting NCT05817058
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 active_not_recruiting NCT05875805
A Telehealth Advance Care Planning Intervention No drug interventions supportive_care Not Available recruiting NCT06128070
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome prevention 2 recruiting NCT06158100
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) treatment 1 not_yet_recruiting NCT06301425
MRD Response-adapted Allo-HSCT for Adverse-risk AML No drug interventions treatment Not Available recruiting NCT06370000
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality treatment 4 not_yet_recruiting NCT06498973
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant treatment 1 not_yet_recruiting NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 1 not_yet_recruiting NCT03113643
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) treatment 1 recruiting NCT03724084
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement treatment 1 / 2 terminated NCT04570709
RN-Led Palliative and Supportive Care Intervention No drug interventions supportive_care Not Available active_not_recruiting NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 treatment 3 recruiting NCT04789408
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 terminated NCT05424562
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada No drug interventions Not Available Not Available recruiting NCT05457010
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS No drug interventions treatment 1 recruiting NCT05986240
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML treatment 1 recruiting NCT06299462
PTCy and ATG for MSD and MUD Transplants prevention 1 / 2 recruiting NCT06337331
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant treatment 2 withdrawn NCT06451861
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML treatment 2 not_yet_recruiting NCT06452732
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML No drug interventions Not Available Not Available not_yet_recruiting NCT00590187
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients treatment 2 completed NCT03466294
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML treatment 2 active_not_recruiting NCT03586609
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 recruiting NCT04083170
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers treatment 2 terminated NCT04190550
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT04277442
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT04580121
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. treatment 1 completed NCT05010772
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission treatment 1 recruiting NCT05183035
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) treatment 3 recruiting NCT05883956
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia treatment 3 active_not_recruiting NCT06439199
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy No drug interventions Not Available Not Available not_yet_recruiting NCT06441084
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation No drug interventions prevention 1 not_yet_recruiting NCT01305499
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) treatment 2 active_not_recruiting NCT03164057
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT03760237
Cardiovascular Function in Acute Leukemia No drug interventions Not Available Not Available completed NCT04526288
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease treatment 2 terminated NCT05316701
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 3 active_not_recruiting NCT05304156
Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study" No drug interventions Not Available Not Available recruiting NCT05326919
The Patient Cohort of the National Center for Precision Medicine in Leukemia No drug interventions Not Available Not Available recruiting NCT05580861
Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment treatment 1 / 2 recruiting NCT05918692
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia No drug interventions treatment 1 recruiting NCT06195891
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT06225128
Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT06387069
A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia No drug interventions treatment 3 recruiting NCT06429098
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML treatment 2 recruiting NCT06429670
Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory No drug interventions Not Available Not Available completed NCT03333005
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia other 1 completed NCT03310918
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy No drug interventions supportive_care Not Available recruiting NCT03900949
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia treatment 1 suspended NCT04081259
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy treatment 1 recruiting NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation treatment 1 / 2 recruiting NCT04797767
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms treatment 1 suspended NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT06158828
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML treatment 1 / 2 recruiting NCT02848001
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes treatment 1 terminated NCT03678493
A Study of FMT in Patients With AML Allo HSCT in Recipients treatment 2 completed NCT03860844
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia treatment 2 terminated NCT04173533
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT treatment 3 active_not_recruiting NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT05735184
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML treatment 1 recruiting NCT05772273
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT treatment Not Available recruiting NCT06379360
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients treatment 2 recruiting NCT00674479
INCB018424 in Patients With Advanced Hematologic Malignancies treatment 2 completed NCT03008187
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia treatment 1 / 2 completed NCT02942758
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML treatment 2 terminated NCT02971397
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT03589729
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers supportive_care 2 recruiting NCT04669210
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT prevention 2 active_not_recruiting NCT04942730
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) treatment 2 completed NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases No drug interventions treatment 2 recruiting NCT06323590
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study No drug interventions Not Available Not Available recruiting NCT01688011
Connect® Myeloid Disease Registry Not Available Not Available recruiting NCT02181699
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 terminated NCT02658487
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT03426605
A Study of LAM-003 in Patients With Acute Myeloid Leukemia No drug interventions treatment 1 completed NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT03955783
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies treatment 1 active_not_recruiting NCT03964506
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant No drug interventions treatment 0 recruiting NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study No drug interventions Not Available Not Available recruiting NCT05155709
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. treatment 1 active_not_recruiting NCT06197672
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant No drug interventions treatment 1 recruiting NCT06386302
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia treatment Not Available not_yet_recruiting NCT02250937
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 recruiting NCT04185428
Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia No drug interventions supportive_care Not Available suspended NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT05433532
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients treatment 2 completed NCT05503134
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML treatment 1 / 2 recruiting NCT06326268
Interest of Light Therapy in Hematology - The PHOTO-TREAT Study No drug interventions supportive_care Not Available recruiting NCT01751997
Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors No drug interventions treatment 2 / 3 completed NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT03503409
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT03999723
Combining Active and Passive DNA Hypomethylation No drug interventions treatment 2 recruiting NCT04571645
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia treatment 3 terminated NCT04778397
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated treatment 3 terminated NCT04827719
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS treatment 2 active_not_recruiting NCT05035706
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors No drug interventions treatment 0 recruiting NCT06369662
CD155 Expression in Acute Myeloid Leukemia No drug interventions Not Available Not Available active_not_recruiting NCT02719574
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation treatment 1 / 2 completed NCT03455504
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia treatment 2 active_not_recruiting NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy treatment 2 active_not_recruiting NCT03844997
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT04229979
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 treatment 3 active_not_recruiting NCT04730258
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML treatment 1 / 2 recruiting NCT04822766
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia No drug interventions treatment Not Available recruiting NCT04982354
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT05233618
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002) treatment 1 recruiting NCT05367401
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants treatment 1 / 2 withdrawn NCT05939180
VA vs DA for Newly Diagnosed Hig-risk AML treatment 2 / 3 recruiting NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 recruiting NCT06351306
DEC-C and Thioguanine for R/R AML treatment 2 recruiting NCT06355583
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial No drug interventions prevention 2 not_yet_recruiting NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 recruiting NCT04994808
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia treatment 2 recruiting NCT05319249
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia treatment 1 / 2 not_yet_recruiting NCT04940468
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology No drug interventions prevention Not Available recruiting NCT01595295
Registry on Hypomethylating Agents in Myeloid Neoplasms No drug interventions Not Available Not Available completed NCT02446145
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients treatment 2 terminated NCT04914845
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT06118788
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT06328179
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. treatment Not Available recruiting NCT01386619
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) treatment 1 / 2 completed NCT03921047
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT04068597
Study to Evaluate CCS1477 in Haematological Malignancies treatment 1 / 2 recruiting NCT04067336
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT04195945
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients treatment 2 recruiting NCT04243785
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 recruiting NCT04282187
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms treatment 2 recruiting NCT04801797
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML treatment 2 recruiting NCT05941585
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia treatment Not Available recruiting NCT06313437
Revumenib in Combination With 7+3 + Midostaurin in AML treatment 1 not_yet_recruiting NCT01861314
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03690115
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients treatment 2 active_not_recruiting NCT04902833
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms No drug interventions Not Available Not Available recruiting NCT00235560
Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients treatment 2 completed NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT03009240
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03042689
Study of Regorafenib in Patients With Advanced Myeloid Malignancies treatment 1 completed NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation treatment 2 active_not_recruiting NCT03595787
COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions supportive_care Not Available recruiting NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention treatment 1 active_not_recruiting NCT04500587
Phase 1 First in Human Study of ZN-d5 as a Single Agent No drug interventions treatment 1 recruiting NCT04625413
A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists No drug interventions supportive_care Not Available completed NCT04968860
Oral Health Condition and Quality of Life in Children With Leukemia No drug interventions Not Available Not Available terminated NCT05105152
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML No drug interventions treatment 1 recruiting NCT05401097
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) treatment 2 recruiting NCT05720988
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia treatment 1 withdrawn NCT06046313
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS treatment 2 recruiting NCT06050941
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS treatment 2 not_yet_recruiting NCT06152809
CIML NK Cells With Venetoclax for AML treatment 1 active_not_recruiting NCT06286332
Music Therapy in Acute Leukemia Patients With Fatigue No drug interventions supportive_care Not Available not_yet_recruiting NCT06295029
Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics No drug interventions Not Available Not Available not_yet_recruiting NCT03494569
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT03564288
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) No drug interventions treatment 1 completed NCT03836209
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT04914676
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission treatment 2 active_not_recruiting NCT05029141
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT06146257
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes No drug interventions treatment 1 recruiting NCT03467386
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia treatment 1 recruiting NCT03374332
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT03828773
PTX3-targeted Antifungal Prophylaxis prevention Not Available recruiting NCT04460235
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma treatment 4 recruiting NCT04512105
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT05589896
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT06245746
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia No drug interventions treatment 1 not_yet_recruiting NCT06256627
The Maintenance Treatment of "ITIVA" in AML Patients other Not Available recruiting NCT04024761
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation treatment 1 enrolling_by_invitation NCT04920188
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available active_not_recruiting NCT00898755
Collecting and Storing Tissue From Young Patients With Cancer No drug interventions Not Available Not Available recruiting NCT03110354
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) No drug interventions treatment 1 terminated NCT04358393
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS treatment 1 / 2 recruiting NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies treatment 1 terminated NCT05260528
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics treatment 2 recruiting NCT05309733
A Long-term Follow-up Study of Patients Who Received VOR33 No drug interventions Not Available Not Available recruiting NCT05607199
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics treatment 1 recruiting NCT05641259
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML treatment 1 recruiting NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT05716009
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML treatment 1 recruiting NCT02677922
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy treatment 1 / 2 active_not_recruiting NCT06218771
A Study of TQB3454 Tablets in Patients With Blood Tumors No drug interventions treatment 1 / 2 recruiting NCT02038777
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies treatment 1 completed NCT01898793
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 1 / 2 terminated NCT02461537
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML treatment 3 completed NCT02367456
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients treatment 1 completed NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT03987958
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) No drug interventions Not Available Not Available suspended NCT06034275
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies No drug interventions treatment 1 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT03969446
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory treatment 1 recruiting NCT04090268
Precision Exercise in Children With Malignant Hemopathies No drug interventions treatment Not Available recruiting NCT04219163
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen No drug interventions treatment 1 recruiting NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT05823480
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS treatment 1 suspended NCT02789254
FLYSYN in MRD Positive AML No drug interventions treatment 1 / 2 completed NCT04522895
IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT treatment 2 active_not_recruiting NCT06180863
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients treatment 2 withdrawn NCT02400255
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients treatment 2 completed NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation supportive_care 2 active_not_recruiting NCT04842604
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML treatment 3 completed NCT04817241
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients treatment 1 / 2 active_not_recruiting NCT05215639
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets No drug interventions Not Available Not Available completed NCT06055621
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE treatment 2 not_yet_recruiting NCT03178617
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma No drug interventions supportive_care Not Available active_not_recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT03793478
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood treatment 1 / 2 recruiting NCT04070768
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 treatment 1 active_not_recruiting NCT05201183
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies treatment 1 / 2 withdrawn NCT04209725
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia treatment 2 terminated NCT05305859
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML treatment 2 recruiting NCT05603884
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 2 recruiting NCT06162325
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients No drug interventions Not Available Not Available enrolling_by_invitation NCT00697684
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant treatment 1 completed NCT03896854
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 recruiting NCT04257175
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression treatment 2 / 3 recruiting NCT05597306
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05583175
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies treatment 2 recruiting NCT05968170
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant No drug interventions treatment Not Available not_yet_recruiting NCT02543879
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT05918198
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia treatment 2 recruiting NCT02498665
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies treatment 1 completed NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors treatment 1 recruiting NCT02520011
Alvocidib Biomarker-driven Phase 2 AML Study treatment 2 terminated NCT03961919
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant treatment 2 completed NCT05319587
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) treatment 1 / 2 recruiting NCT06133556
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML No drug interventions treatment 2 not_yet_recruiting NCT01823198
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies treatment 1 / 2 completed NCT03671564
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 completed NCT03728699
Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy No drug interventions Not Available Not Available completed NCT05170828
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies treatment 1 withdrawn NCT05263284
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05943314
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia No drug interventions treatment Not Available withdrawn NCT06110208
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML No drug interventions treatment 0 recruiting NCT00804856
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia treatment 2 completed NCT01518556
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT02073838
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML treatment 2 completed NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT02743611
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma treatment 1 / 2 terminated NCT02771197
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant treatment 2 completed NCT03699475
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS treatment 2 / 3 terminated NCT04075747
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia treatment 1 completed NCT04166929
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS treatment 2 terminated NCT04415008
Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia treatment 2 recruiting NCT04485052
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia treatment 1 / 2 suspended NCT04614636
FT538 in Subjects With Advanced Hematologic Malignancies treatment 1 terminated NCT04774744
Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia No drug interventions supportive_care Not Available completed NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT05377827
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies treatment 1 recruiting NCT05471700
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients treatment 1 / 2 recruiting NCT05735717
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies treatment 2 recruiting NCT05995041
Universal CAR-T Cells Targeting AML No drug interventions treatment 1 recruiting NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies No drug interventions treatment 1 recruiting NCT06068621
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia treatment 2 recruiting NCT06073730
Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients No drug interventions treatment 3 not_yet_recruiting NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention supportive_care 3 completed NCT04002115
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML treatment 2 terminated NCT02873338
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT06008405
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy treatment 1 recruiting NCT03224819
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) treatment 0 terminated NCT03531918
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm treatment 1 / 2 completed NCT03537560
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML No drug interventions Not Available Not Available completed NCT04052126
An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies No drug interventions supportive_care Not Available completed NCT04671693
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. No drug interventions prevention Not Available recruiting NCT04872478
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL No drug interventions treatment 1 recruiting NCT03030612
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) treatment 1 / 2 completed NCT02936089
Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ No drug interventions treatment Not Available completed NCT04241549
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment treatment 1 completed NCT04385290
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) treatment 1 / 2 recruiting NCT05904106
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML treatment 2 not_yet_recruiting NCT05979675
Acute Myeloid Leukemia Registry No drug interventions Not Available Not Available recruiting NCT05982756
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML treatment 1 recruiting NCT03267186
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant treatment 2 completed NCT03867682
Venetoclax and Lintuzumab-Ac225 in AML Patients treatment 1 / 2 recruiting NCT05005299
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation treatment 1 recruiting NCT05501171
Psychological Mobile App for Patients With AML No drug interventions supportive_care Not Available terminated NCT05595135
Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study No drug interventions health_services_research Not Available withdrawn NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT02665065
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 3 active_not_recruiting NCT03932318
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients treatment 1 / 2 withdrawn NCT05703542
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT01494103
Administration of Donor T Cells With the Caspase-9 Suicide Gene treatment 1 active_not_recruiting NCT02842827
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) treatment 1 / 2 completed NCT03050216
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML treatment 2 completed NCT03420430
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care Not Available Not Available temporarily_not_available NCT04923919
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia No drug interventions treatment 0 recruiting NCT05949762
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly No drug interventions treatment 1 / 2 recruiting NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT04687098
Risk-adapted Therapy for Primary Acute Myeloid Leukemia treatment 2 completed NCT05919199
PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia No drug interventions Not Available Not Available enrolling_by_invitation NCT02141828
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene treatment 1 completed NCT04887259
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML treatment 1 / 2 active_not_recruiting NCT04896112
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia No drug interventions treatment 1 withdrawn NCT05909293
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission treatment Not Available recruiting NCT03634228
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia treatment 1 / 2 terminated NCT04027309
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy treatment 3 active_not_recruiting NCT04230564
Acute Myeloid Leukemia Real World Treatment Patterns Not Available Not Available withdrawn NCT04484532
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers supportive_care 0 completed NCT05166135
Latin American Real-world Study in Acute Leukemia No drug interventions Not Available Not Available completed NCT05893329
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia treatment Not Available not_yet_recruiting NCT05264883
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML treatment 3 recruiting NCT03417154
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS treatment 2 completed NCT04146038
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease treatment 2 completed NCT05140811
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT05471323
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML No drug interventions treatment 1 recruiting NCT00413439
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy prevention 2 / 3 completed NCT04644419
Chemotherapy-related Cognitive Impairment and Acute Leukemia No drug interventions Not Available Not Available completed NCT04645199
National Longitudinal Cohort of Hematological Diseases No drug interventions Not Available Not Available recruiting NCT04745676
A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions supportive_care Not Available active_not_recruiting NCT05330377
GM-CLAG in Relapsed/Refractory FLT3-mutated AML treatment 1 withdrawn NCT03416179
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia treatment 3 completed NCT03280030
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML treatment 2 completed NCT05823714
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT No drug interventions treatment 2 recruiting NCT02891278
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML treatment 1 completed NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies treatment 1 terminated NCT04067180
Randomized Clinical Study Assessing Haplo vs. URD in AML No drug interventions treatment Not Available terminated NCT05593185
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS Not Available Not Available available NCT05805098
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML treatment 2 / 3 recruiting NCT02878785
Decitabine and Talazoparib in Untreated AML and R/R AML treatment 1 / 2 completed NCT04173585
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib treatment 2 completed NCT05266950
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT05791890
GilteRInf 2022 Study (Gilteritinib Related Infections) Not Available Not Available active_not_recruiting NCT05448599
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS No drug interventions treatment 1 / 2 recruiting NCT02845297
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients treatment 2 completed NCT04476199
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT treatment 2 completed NCT00893399
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation treatment 3 completed NCT01420926
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT01238211
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT02775903
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) treatment 2 completed NCT03303339
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep treatment 2 active_not_recruiting NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT03194932
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage treatment 1 completed NCT04310592
Natural Killer Cell (CYNK-001) Infusions in Adults With AML treatment 1 recruiting NCT04669067
TL-895 and KRT-232 Study in Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT02743351
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies No drug interventions prevention 1 / 2 completed NCT04518345
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia treatment 0 completed NCT05223699
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) No drug interventions treatment 1 terminated NCT03388749
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT00849147
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) No drug interventions treatment 2 completed NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT05599360
Vyxeos for Induction of Low- or Intermediate-risk. treatment 2 recruiting NCT05587088
Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) No drug interventions treatment 1 / 2 not_yet_recruiting NCT05563207
Application of Health Education Path of Traditional Chinese Medicine Nursin No drug interventions supportive_care Not Available completed NCT05558943
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital No drug interventions Not Available Not Available not_yet_recruiting NCT05445011
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05431257
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling treatment 2 recruiting NCT05383014
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. No drug interventions Not Available Not Available not_yet_recruiting NCT05382390
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial treatment 3 recruiting NCT05356169
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia No drug interventions treatment 2 / 3 not_yet_recruiting NCT05333705
Donor Immune Cell Therapy for Acute Myeloid Leukemia treatment 1 recruiting NCT05297123
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid treatment 1 recruiting NCT05279859
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies treatment 1 / 2 withdrawn NCT05270200
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse treatment 1 / 2 recruiting NCT05258799
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study treatment Not Available recruiting NCT05249894
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy No drug interventions Not Available Not Available recruiting NCT05248685
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT05215015
Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia treatment 0 recruiting NCT05169307
CPX-351 Real-World Effectiveness and Safety Study No drug interventions Not Available Not Available completed NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy No drug interventions Not Available Not Available not_yet_recruiting NCT05150561
Muscle Dysfunction in Patients With Haematological Diseases No drug interventions Not Available Not Available recruiting NCT05149339
Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia treatment 1 / 2 completed NCT05123352
Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies No drug interventions Not Available Not Available not_yet_recruiting NCT05066958
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT No drug interventions prevention 1 / 2 recruiting NCT05061147
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) treatment 1 / 2 recruiting NCT05057299
Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes No drug interventions Not Available Not Available completed NCT05055791
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 / 2 not_yet_recruiting NCT05053425
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML treatment Not Available recruiting NCT05042531
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia treatment Not Available recruiting NCT05023707
Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 recruiting NCT05017883
TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia No drug interventions treatment Not Available recruiting NCT05016752
Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection No drug interventions Not Available Not Available recruiting NCT05008575
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05001451
Study of GDX012 in Patients With MRD Positive AML treatment 1 terminated NCT05000801
Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia No drug interventions treatment Not Available recruiting NCT04992949
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm No drug interventions treatment 2 recruiting NCT04980885
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT04943757
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies treatment 2 recruiting NCT04931992
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse. No drug interventions Not Available Not Available recruiting NCT04920500
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients treatment Not Available recruiting NCT04910698
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia No drug interventions Not Available Not Available completed NCT04867928
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia treatment 2 recruiting NCT04858594
Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy No drug interventions Not Available Not Available terminated NCT04824924
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy treatment 2 not_yet_recruiting NCT04788420
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML Not Available Not Available completed NCT04764513
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT No drug interventions treatment 1 / 2 recruiting NCT04763928
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax treatment 2 recruiting NCT04762485
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia No drug interventions treatment 1 / 2 recruiting NCT04722952
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML treatment 3 recruiting NCT04687761
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old treatment 1 / 2 recruiting NCT04678466
Flotetuzumab Expanded Access Program Not Available Not Available no_longer_available NCT04679285
Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases No drug interventions treatment 0 recruiting NCT04641910
Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT04635384
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test No drug interventions Not Available Not Available recruiting NCT04599543
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia No drug interventions treatment 0 not_yet_recruiting NCT04589728
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 Not Available Not Available recruiting NCT04543305
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT04517175
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? No drug interventions Not Available Not Available not_yet_recruiting NCT04460963
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches No drug interventions basic_science Not Available recruiting NCT04450784
ObServatory Children Acute RElated Therapy Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT04369287
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT04353479
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia treatment 2 not_yet_recruiting NCT04327037
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia treatment 1 completed NCT04282174
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies treatment 2 withdrawn NCT04259372
Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients No drug interventions Not Available Not Available completed NCT04248595
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML treatment 2 recruiting NCT04242849
IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up No drug interventions Not Available Not Available completed NCT04221971
NK Cell Infusion for Patients With Acute Myeloid Leukemia treatment 1 unknown_status NCT04215822
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT04209712
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease No drug interventions treatment 0 unknown_status NCT04168138
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients treatment Not Available recruiting NCT04156256
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies No drug interventions treatment 0 unknown_status NCT04133220
Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT04112589
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment treatment 1 / 2 active_not_recruiting NCT04093505
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) treatment 3 terminated NCT04090736
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy treatment 3 active_not_recruiting NCT04083911
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 treatment 3 unknown_status NCT04070807
Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2 No drug interventions Not Available Not Available unknown_status NCT04060485
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results No drug interventions Not Available Not Available recruiting NCT04044209
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS treatment 2 withdrawn NCT04038437
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML treatment 1 completed NCT04022785
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT04015024
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients No drug interventions treatment 2 unknown_status NCT04013880
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 / 2 withdrawn NCT04010877
Multiple CAR-T Cell Therapy Targeting AML No drug interventions treatment 1 / 2 recruiting NCT04006496
AML Expressive Writing No drug interventions supportive_care Not Available terminated NCT03988205
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia treatment 4 terminated NCT03926624
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage treatment 3 recruiting NCT03922477
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia treatment 1 terminated NCT03902769
Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients. No drug interventions treatment Not Available not_yet_recruiting NCT03885076
Gamma Delta T Cells in AML No drug interventions Not Available Not Available unknown_status NCT03825887
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients prevention 3 completed NCT03823352
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients treatment 2 completed NCT03800095
Early Palliative Care for Patients With Haematological Malignancies No drug interventions treatment 3 recruiting NCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies treatment 1 terminated NCT03796533
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity health_services_research Not Available recruiting NCT03793517
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT treatment 2 / 3 recruiting NCT03789981
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT03769532
MRD-guided Treatment in NPM1mut AML Patients treatment 2 recruiting NCT03760666
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 / 2 terminated NCT03761069
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias treatment 1 terminated NCT03760445
HDM201 Added to CT in R/R or Newly Diagnosed AML treatment 1 / 2 withdrawn NCT03755856
Long-term Outcomes for Acute Myeloid Leukemia Patients No drug interventions Not Available Not Available unknown_status NCT03723057
Expanded Access for AG-221 Not Available Not Available no_longer_available NCT03719183
Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML No drug interventions Not Available Not Available completed NCT03715621
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT No drug interventions Not Available Not Available unknown_status NCT03705858
Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia treatment 1 withdrawn NCT03701217
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML treatment 2 / 3 unknown_status NCT03696537
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT treatment 1 terminated NCT03672851
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia No drug interventions treatment 1 terminated NCT03665480
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML supportive_care 2 / 3 unknown_status NCT03661515
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML treatment 1 completed NCT03655145
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation No drug interventions treatment 3 not_yet_recruiting NCT03642236
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML treatment 2 / 3 enrolling_by_invitation NCT03609060
Dexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML) treatment 2 active_not_recruiting NCT03597321
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML No drug interventions treatment 2 not_yet_recruiting NCT03594149
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients prevention 3 unknown_status NCT03582241
NGS in AML Relapse No drug interventions Not Available Not Available unknown_status NCT03563560
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia treatment 1 completed NCT03556982
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） No drug interventions treatment 1 / 2 unknown_status NCT03549351
Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival No drug interventions Not Available Not Available terminated NCT03530085
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT treatment 2 / 3 unknown_status NCT03516760
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT03515707
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia treatment 2 withdrawn NCT03507842
A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML. treatment 3 unknown_status NCT03454984
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation prevention 2 unknown_status NCT03449745
Immune Checkpoint Receptors in AML-Leukemic Initiating Cells No drug interventions Not Available Not Available completed NCT03442452
AML Electronic Decision Aid No drug interventions supportive_care Not Available completed NCT03435341
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain No drug interventions Not Available Not Available completed NCT03429387
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia No drug interventions diagnostic Not Available completed NCT03410407
Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available terminated NCT03393611
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT03381118
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients treatment 2 terminated NCT03381781
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations treatment 2 unknown_status NCT03358719
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 completed NCT03356080
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess treatment 2 unknown_status NCT03350152
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience. No drug interventions Not Available Not Available completed NCT03338348
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 treatment 2 completed NCT03311815
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia. No drug interventions Not Available Not Available completed NCT03301597
NLA101 in Adults Receiving High Dose Chemotherapy for AML prevention 2 terminated NCT03287128
Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg® Not Available Not Available unknown_status NCT03284593
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition Not Available Not Available active_not_recruiting NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies treatment 1 completed NCT03257241
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old treatment 3 recruiting NCT03256071
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT treatment 2 / 3 unknown_status NCT03234985
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT03232268
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies No drug interventions treatment 1 recruiting NCT03207334
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) treatment 2 withdrawn NCT03197714
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia treatment 1 completed NCT03190499
Quality of Life in Children With Cancer No drug interventions Not Available Not Available completed NCT03187691
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia prevention 2 withdrawn NCT03181815
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia treatment 2 unknown_status NCT03156933
Alternative Splicing and Leukemia Initiating Cells No drug interventions Not Available Not Available unknown_status NCT03154190
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer No drug interventions health_services_research Not Available active_not_recruiting NCT03150134
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients treatment 4 unknown_status NCT03148197
Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) No drug interventions Not Available Not Available unknown_status NCT03144245
Study of AMV564 in Patients With AML treatment 1 completed NCT03135028
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults treatment 1 terminated NCT03126864
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia treatment 1 terminated NCT03113071
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS treatment 1 / 2 terminated NCT03108911
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy No drug interventions supportive_care 2 terminated NCT03106428
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 completed NCT03088709
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide prevention 2 recruiting NCT03083054
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT03080766
The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype treatment 2 recruiting NCT03072043
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms treatment 1 / 2 completed NCT03066466
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT prevention 3 withdrawn NCT03038230
MCLA-117 in Acute Myelogenous Leukemia No drug interventions treatment 1 active_not_recruiting NCT03026842
Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) prevention 4 active_not_recruiting NCT03023384
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML No drug interventions Not Available Not Available unknown_status NCT03019939
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia prevention 2 completed NCT02999854
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer prevention 3 terminated NCT02979548
Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy prevention 3 unknown_status NCT02954653
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia treatment 1 terminated NCT02944162
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML treatment 1 / 2 unknown_status NCT02937662
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML treatment 2 unknown_status NCT02933333
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor treatment 4 unknown_status NCT02927106
Beat AML Core Study No drug interventions Not Available Not Available completed NCT02923986
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS treatment 1 / 2 withdrawn NCT02921815
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment No drug interventions Not Available Not Available completed NCT02914977
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia treatment 1 completed NCT02909972
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome treatment 1 completed NCT02900430
Invasives Aspergillosis in Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02899767
Transfusion in Adult Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02892318
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) treatment 1 completed NCT02891551
An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands No drug interventions Not Available Not Available completed NCT02877277
Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study No drug interventions treatment Not Available completed NCT02875743
King's Invasive Aspergillosis Study II prevention 4 completed NCT02875093
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML treatment 1 terminated NCT02870777
MRD-directed Therapy for Low-risk and Intermediate-risk AML. No drug interventions treatment 2 / 3 completed NCT02867891
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial No drug interventions Not Available Not Available completed NCT02863302
Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients No drug interventions supportive_care Not Available unknown_status NCT02861651
Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing No drug interventions Not Available Not Available completed NCT02860793
Role of PTK-7 in Acute Myeloid Leukemias No drug interventions basic_science Not Available completed NCT02860598
Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy No drug interventions Not Available Not Available unknown_status NCT02856178
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients prevention 1 / 2 withdrawn NCT02856464
Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy No drug interventions treatment 2 unknown_status NCT02845232
Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly No drug interventions Not Available Not Available completed NCT02844218
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02834390
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 1 completed NCT02809092
Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia treatment 1 / 2 unknown_status NCT02799147
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia treatment 1 / 2 completed NCT02785900
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 terminated NCT02781467
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) treatment 1 terminated NCT02779283
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia treatment 1 completed NCT02773732
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) treatment 1 / 2 terminated NCT02770820
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia treatment 1 / 2 terminated NCT02765997
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies No drug interventions treatment 2 withdrawn NCT02763475
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents treatment 2 completed NCT02759822
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias No drug interventions Not Available Not Available unknown_status NCT02750254
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation treatment 1 terminated NCT02750995
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML treatment 1 completed NCT02742727
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma treatment 1 / 2 unknown_status NCT02732184
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS treatment 2 completed NCT02717884
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) treatment 1 / 2 unknown_status NCT02715011
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) No drug interventions treatment 1 completed NCT02714790
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02708641
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML treatment 2 completed NCT02698124
Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice Not Available Not Available unknown_status NCT02686593
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML treatment 2 completed NCT02682732
Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia No drug interventions diagnostic Not Available unknown_status NCT02680951
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia treatment 1 withdrawn NCT02678338
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies treatment 1 completed NCT02676856
Hematopoietic Stem Cell Microtransplantation for in AML No drug interventions treatment Not Available unknown_status NCT02676323
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 terminated NCT02671708
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT treatment 2 / 3 completed NCT02670044
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy treatment 1 completed NCT02667093
Samples From Leukemia Patients and Their Donors to Identify Specific Antigens No drug interventions Not Available Not Available unknown_status NCT02619071
ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT02614560
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients treatment 1 / 2 terminated NCT02610777
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) treatment 2 completed NCT02605460
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission treatment 2 unknown_status NCT02602587
Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients No drug interventions basic_science Not Available completed NCT02598752
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation No drug interventions Not Available Not Available completed NCT02582359
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age treatment 1 completed NCT02573363
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT02561455
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial treatment 1 / 2 completed NCT02545283
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 3 terminated NCT02527447
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) No drug interventions Not Available Not Available completed NCT02527174
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia treatment 1 withdrawn NCT02500550
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor prevention 2 completed NCT02493829
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) No drug interventions treatment 1 unknown_status NCT02488408
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS treatment 1 / 2 active_not_recruiting NCT02485353
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML treatment Not Available terminated NCT02472145
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy treatment 2 / 3 completed NCT02472691
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT treatment 2 completed NCT02462265
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients treatment 2 suspended NCT02450877
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. treatment 2 completed NCT02435550
iCare for Cancer Patients No drug interventions diagnostic Not Available terminated NCT02432911
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old treatment Not Available unknown_status NCT02428543
Ponatinib for FLT3-ITD Acute Myelogenous Leukemia treatment 1 / 2 active_not_recruiting NCT02427919
Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML supportive_care 2 / 3 unknown_status NCT02412475
Epigenetic Reprogramming in Relapse AML treatment 1 terminated NCT02410252
Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies No drug interventions other Not Available completed NCT02403310
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML treatment 1 completed NCT02381548
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia treatment 1 terminated NCT02349178
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT treatment 2 terminated NCT02345915
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia No drug interventions basic_science Not Available unknown_status NCT02341495
Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 treatment 2 terminated NCT02337595
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation No drug interventions prevention 1 / 2 completed NCT02335814
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT02328755
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia treatment 1 / 2 completed NCT02319135
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 completed NCT02310243
Study of Palbociclib in MLL-rearranged Acute Leukemias treatment 1 / 2 unknown_status NCT02308761
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 completed NCT02303782
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) treatment 1 / 2 withdrawn NCT02298166
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations treatment 3 terminated NCT02294552
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT treatment 2 completed NCT02293993
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia treatment 1 completed NCT02283190
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) other 1 completed NCT02282215
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia supportive_care 2 completed NCT02277847
Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia treatment 4 unknown_status NCT02276651
Observational Trial of a Therapeutic Platelet Transfusion Regimen No drug interventions Not Available Not Available terminated NCT02275663
Azacytidine Plus FLAG for Relapsed or Refractory AML treatment 2 unknown_status NCT02270788
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies treatment 1 completed NCT02264873
Phase I, Dose Escalation Study of Decitabine treatment 1 completed NCT02258490
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation Not Available Not Available no_longer_available NCT02238522
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML No drug interventions treatment 1 withdrawn NCT02236013
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT02226497
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy No drug interventions device_feasibility Not Available terminated NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT02188290
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation No drug interventions Not Available Not Available completed NCT02182596
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML treatment 1 / 2 completed NCT02176109
Metabolism Des LAM No drug interventions Not Available Not Available unknown_status NCT02171117
Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia No drug interventions treatment 3 unknown_status NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies No drug interventions Not Available Not Available completed NCT02156297
Sorafenib to Treat FLT3-ITD AML No drug interventions Not Available Not Available unknown_status NCT02140606
Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML) treatment 1 unknown_status NCT02117115
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation screening 0 completed NCT02101983
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) treatment Not Available completed NCT02093403
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT02072811
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia treatment 3 unknown_status NCT02057770
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 terminated NCT02040506
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML No drug interventions treatment 1 completed NCT02027064
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT treatment 4 unknown_status NCT02016729
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia treatment 1 completed NCT02016833
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity No drug interventions Not Available Not Available completed NCT02014558
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 completed NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination No drug interventions treatment 1 / 2 unknown_status NCT02003573
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) treatment 1 terminated NCT01994837
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) treatment 2 completed NCT01985061
Evaluation of 3 Different Doses of IV Busulfan treatment 2 unknown_status NCT01976442
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia No drug interventions Not Available Not Available completed NCT01965171
Transfusional Iron Overload Among Leukemia Survivors No drug interventions Not Available Not Available completed NCT01960387
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia treatment 2 terminated NCT01947322
Haploidentical NK-cell Infusion in Acute Myeloid Leukemia treatment 1 / 2 completed NCT01926587
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine treatment 1 / 2 completed NCT01912274
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 2 completed NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms treatment 1 terminated NCT01889407
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients Not Available Not Available unknown_status NCT01853228
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 terminated NCT01843634
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia No drug interventions treatment 0 completed NCT01835587
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). treatment 1 / 2 completed NCT01830361
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML treatment 2 completed NCT01829503
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 2 completed NCT01819558
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy No drug interventions treatment 1 / 2 completed NCT01810705
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia treatment 2 completed NCT01804101
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment Not Available completed NCT01802333
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia treatment 3 completed NCT01794299
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor No drug interventions prevention 2 completed NCT01794169
Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML treatment 2 terminated NCT01793025
Mismatched Donor Cells to Treat Acute Myeloid Leukemia No drug interventions treatment 1 unknown_status NCT01785953
Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia No drug interventions Not Available Not Available unknown_status NCT01773395
GVAX vs. Placebo for MDS/AML After Allo HSCT treatment 2 terminated NCT01770158
Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) No drug interventions Not Available Not Available terminated NCT01766375
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient treatment 3 unknown_status NCT01747499
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation treatment 1 / 2 terminated NCT01743859
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia treatment 2 completed NCT01734304
DC Vaccination for Postremission Therapy in AML No drug interventions treatment 1 / 2 completed NCT01713582
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) treatment 1 completed NCT01700751
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation treatment 1 completed NCT01690624
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse treatment 1 completed NCT01687400
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 2 completed NCT01687387
Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) treatment 2 completed NCT01685411
Busulfan and Cyclophosphamide Followed By ALLO BMT treatment Not Available terminated NCT01683123
Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT No drug interventions Not Available Not Available completed NCT01677949
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia treatment 2 withdrawn NCT01662505
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) treatment 1 completed NCT01656252
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission treatment 1 / 2 terminated NCT01636609
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 terminated NCT01632852
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission treatment 1 completed NCT01627041
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT01617226
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS treatment 2 completed NCT01615757
Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation treatment 3 unknown_status NCT01599429
Study of the Predictive Marker FLT in Patients Suffering From AML No drug interventions Not Available Not Available withdrawn NCT01588951
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior treatment 2 / 3 terminated NCT01578954
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction treatment 1 completed NCT01573247
Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia treatment 1 / 2 terminated NCT01541280
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 2 completed NCT01534260
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype treatment 1 / 2 completed NCT01520558
CNDO-109-AANK for AML in First Complete Remission (CR1) treatment 1 / 2 unknown_status NCT01519011
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine treatment 1 completed NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies treatment Not Available completed NCT01489722
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients No drug interventions treatment 1 terminated NCT01484171
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia treatment 3 unknown_status NCT01478074
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia treatment 1 withdrawn NCT01477606
Protocol in Acute Myeloid Leukemia With FLT3-ITD treatment 2 completed NCT01475370
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) No drug interventions treatment 1 completed NCT01468467
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) treatment 1 completed NCT01455506
PRO#0118: Decitabine Plus Mini Flu-Bu treatment 1 completed NCT01455025
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia treatment 1 terminated NCT01452646
Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia No drug interventions treatment 2 completed NCT01451268
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) treatment 1 / 2 unknown_status NCT01446081
An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy No drug interventions supportive_care 2 completed NCT01433965
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 completed NCT01423175
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS treatment 2 unknown_status NCT01399840
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies treatment 1 completed NCT01390311
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant treatment 1 completed NCT01390337
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 1 completed NCT01385787
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT01382147
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML) treatment 3 completed NCT01370213
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases treatment 2 completed NCT01369368
Treatment of Acute Leukemia Relapse After Allotransplantation treatment 1 / 2 unknown_status NCT01361334
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible treatment 2 completed NCT01358734
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT01349049
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor treatment 2 completed NCT01347996
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia treatment 4 completed NCT01344876
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplant supportive_care 2 terminated NCT01332786
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia treatment 1 completed NCT01329471
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available unknown_status NCT01307579
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia supportive_care 3 completed NCT01303796
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 completed NCT01301820
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) treatment 2 completed NCT01297543
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia supportive_care 1 / 2 completed NCT01295307
Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 2 completed NCT01277484
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML treatment 1 unknown_status NCT01266083
WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) No drug interventions treatment 2 completed NCT01252667
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant treatment 2 completed NCT01249820
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease other 2 completed NCT01246752
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR treatment 3 terminated NCT01247493
Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) treatment 2 completed NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant treatment 3 completed NCT01222143
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia treatment 1 / 2 terminated NCT01211457
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) treatment 1 / 2 unknown_status NCT01203033
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP) No drug interventions Not Available Not Available completed NCT01200017
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant No drug interventions Not Available Not Available no_longer_available NCT01195506
Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available unknown_status NCT01176422
Telomere and Telomerase No drug interventions Not Available Not Available withdrawn NCT01174888
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia treatment 1 completed NCT01170598
Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy No drug interventions supportive_care 2 completed NCT01169012
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias basic_science 1 completed NCT01168219
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies treatment 1 / 2 withdrawn NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors treatment 2 completed NCT01149408
Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients treatment 1 completed NCT01146977
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1) No drug interventions treatment 2 unknown_status NCT01142375
Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells No drug interventions Not Available Not Available unknown_status NCT01133886
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure treatment 2 unknown_status NCT01110824
Prevention of Left Ventricular Dysfunction During Chemotherapy prevention 3 completed NCT01074047
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) treatment 3 completed NCT01067274
ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) treatment 3 withdrawn NCT01066494
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) treatment 2 unknown_status NCT01065545
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia treatment 1 withdrawn NCT01055483
A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia treatment 1 completed NCT01054937
Single Dose Study With 4SC-203 in Healthy Volunteers treatment 1 completed NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT01039363
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia treatment 2 unknown_status NCT01035502
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia treatment 2 completed NCT01036009
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies No drug interventions treatment 2 completed NCT01034410
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia treatment 2 terminated NCT01034839
High-dose Cytarabine and Survival in AML No drug interventions Not Available Not Available completed NCT01027923
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) treatment 1 terminated NCT01025778
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia treatment 2 completed NCT01025154
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction treatment 2 completed NCT01016600
Azacitidine and Lenalidomide for Acute Myeloid Leukemia treatment 1 / 2 completed NCT01015742
Unrelated Double Umbilical Cord Blood Units Transplantation No drug interventions treatment 2 / 3 unknown_status NCT01010373
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients treatment 2 suspended NCT01001143
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) treatment 1 completed NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy treatment 1 completed NCT00990054
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT00989261
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) treatment 2 completed NCT00988013
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies No drug interventions treatment Not Available completed NCT00969891
Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT00968864
T-cell Depleted Alternative Donor Transplantation No drug interventions treatment 2 terminated NCT00965224
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma No drug interventions treatment 2 unknown_status NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy treatment 1 terminated NCT00961142
Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia treatment 2 terminated NCT00957385
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients treatment 2 completed NCT00957580
Trial of Pimasertib in Hematological Malignancies treatment 2 terminated NCT00952588
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients treatment 2 / 3 completed NCT00946647
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). treatment 1 / 2 completed NCT00932412
The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) No drug interventions treatment 2 completed NCT00927498
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old treatment 3 completed NCT00925873
GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly treatment 3 completed NCT00915785
Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities treatment 2 completed NCT00915811
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin treatment 2 terminated NCT00915252
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 2 completed NCT00916045
Pilot Study of Unrelated Cord Blood Transplantation treatment 2 terminated NCT00906945
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia treatment 1 / 2 completed NCT00900809
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia treatment 1 completed NCT00887042
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML treatment 1 / 2 unknown_status NCT00878722
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy treatment 1 / 2 completed NCT00875745
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) treatment 1 completed NCT00864227
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) No drug interventions treatment 2 completed NCT00862719
Sitagliptin Umbilical Cord Blood Transplant Study treatment 2 completed NCT00860639
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk treatment 3 completed NCT00854945
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML treatment 1 / 2 completed NCT00852709
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias treatment 1 terminated NCT00850304
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide treatment 2 completed NCT00839059
Lenalidomide In Patients With Acute Myeloid Leukemia treatment 1 terminated NCT00822393
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) treatment 3 completed NCT00822094
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) No drug interventions treatment 2 completed NCT00809367
Collection and Banking of Leukemia Cells MDS/AML No drug interventions Not Available Not Available completed NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT00806325
Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT00798213
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) treatment 2 terminated NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer treatment 1 / 2 completed NCT00788892
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients treatment 2 completed NCT00783653
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years treatment 1 / 2 completed NCT00780598
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML treatment 2 completed NCT00778375
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00774046
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML treatment 2 completed NCT00766779
HCT Versus CT in Elderly AML No drug interventions treatment 3 terminated NCT00762632
Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia treatment 1 / 2 completed NCT00761722
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma treatment 1 completed NCT00728520
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy treatment 2 unknown_status NCT00727766
Oral Clofarabine for Acute Myeloid Leukemia treatment 1 completed NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT00718250
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 No drug interventions treatment 1 unknown_status NCT00718159
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia treatment 1 completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT00703820
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia treatment 3 completed NCT00701766
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia treatment 2 completed NCT00691938
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT00689000
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) treatment 1 / 2 completed NCT00678275
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia No drug interventions treatment 3 completed NCT00669890
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML treatment 1 terminated NCT00667927
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission treatment 1 completed NCT00660036
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia treatment 1 terminated NCT00658411
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation prevention Not Available terminated NCT00636922
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia treatment 1 unknown_status NCT00637052
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia treatment 1 / 2 completed NCT00632749
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment treatment 2 completed NCT00629798
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) treatment 2 completed NCT00615784
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia treatment 2 terminated NCT00607997
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia treatment 2 completed NCT00606216
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy No drug interventions Not Available Not Available completed NCT00593645
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation treatment 2 terminated NCT00593554
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies treatment 2 terminated NCT00594555
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia treatment 2 withdrawn NCT00590837
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old treatment 3 completed NCT00569179
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies No drug interventions treatment 1 terminated NCT00546897
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities treatment 2 completed NCT00542971
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) treatment 1 / 2 completed NCT00541866
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans treatment 1 / 2 completed NCT00539656
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers No drug interventions treatment 1 / 2 terminated NCT00529880
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML treatment 2 unknown_status NCT00528333
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML treatment 2 completed NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT00513305
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia treatment 3 terminated NCT00513318
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies No drug interventions Not Available Not Available terminated NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT00512252
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia treatment 1 / 2 completed NCT00510939
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia treatment 2 unknown_status NCT00491634
Treosulfan-based Conditioning for Transplantation in AML/MDS treatment 2 completed NCT00488709
Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 4 completed NCT00480987
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) treatment 1 / 2 terminated NCT00480064
Lomustine and Intermediate Dose Cytarabine in Older Patients With AML treatment 3 completed NCT00476541
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia treatment 3 completed NCT00469729
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy treatment 2 / 3 completed NCT00466895
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. treatment 1 completed NCT00462761
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status treatment 1 completed NCT00460447
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation treatment 1 / 2 unknown_status NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies No drug interventions treatment 1 / 2 completed NCT00458250
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H treatment 1 completed NCT00451711
Intermittent Liposomal Amphotericin B Primary Prophylaxis prevention 2 unknown_status NCT00428558
Timed-Sequential Induction in CBF-AML treatment 3 completed NCT00422591
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) treatment 2 completed NCT00416598
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT00394381
Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome No drug interventions treatment 1 / 2 completed NCT00391014
Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis No drug interventions prevention 2 completed NCT00373373
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML treatment 2 completed NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts treatment 2 completed NCT00363025
A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. treatment 3 terminated NCT00342316
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia No drug interventions treatment Not Available completed NCT00329498
L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 2 suspended NCT00328237
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation No drug interventions treatment 2 unknown_status NCT00322673
Study of XL999 in Patients With Acute Myeloid Leukemia (AML) treatment 2 terminated NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT00283114
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 1 completed NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies No drug interventions treatment 2 terminated NCT00266136
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) treatment 3 completed NCT00260832
Trial of Decitabine in Patients With Acute Myeloid Leukemia treatment 3 completed NCT00242515
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 unknown_status NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00199147
Efficacy of G-CSF-Priming in Elderly AML Patients treatment 4 unknown_status NCT00195000
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS treatment 2 completed NCT00188136
Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) treatment 2 completed NCT00172562
Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image No drug interventions Not Available Not Available unknown_status NCT00171249
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia treatment 2 completed NCT00161668
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Not Available Not Available completed NCT00153582
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) No drug interventions treatment 2 unknown_status NCT00150878
Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission No drug interventions treatment 3 terminated NCT00151255
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 completed NCT00151242
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 / 3 completed NCT00145626
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies treatment 2 completed NCT00146120
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result treatment 3 completed NCT00143975
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) treatment 2 completed NCT00143559
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies No drug interventions treatment 2 completed NCT00129948
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 2 terminated NCT00125606
Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide No drug interventions treatment 3 terminated NCT00101179
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia treatment 1 completed NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT00088218
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). diagnostic 2 completed NCT00086099
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia treatment 1 / 2 completed NCT00067028
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) treatment 2 completed NCT00048503
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older treatment 2 completed NCT00045942
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) treatment 1 / 2 completed NCT00037583
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia treatment 2 completed NCT00038051
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies No drug interventions treatment 1 completed NCT03978858
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy treatment 2 not_yet_recruiting NCT05068401
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies treatment 1 not_yet_recruiting NCT04976699
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) treatment 3 active_not_recruiting NCT03826082
PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory CD33-Positive AML or High Risk MDS treatment 1 not_yet_recruiting NCT00466115
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies treatment 2 unknown_status NCT00977782
Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3 treatment 1 / 2 completed NCT00840346
Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) treatment 1 / 2 completed NCT00464217
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years treatment 4 completed NCT02189824
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation No drug interventions treatment 1 unknown_status NCT01621724
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study No drug interventions treatment 1 / 2 completed NCT02724163
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia treatment 3 recruiting NCT02844257
Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia No drug interventions Not Available Not Available completed NCT06345365
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 3 recruiting NCT01063660
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) supportive_care 2 completed NCT04629443
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia treatment 1 / 2 completed NCT06326697
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) other 1 recruiting NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT05712278
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia treatment 1 terminated NCT00530699
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) treatment 1 completed NCT01019161
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) treatment 1 completed NCT01236144
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. treatment 1 / 2 completed NCT01334060
WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation No drug interventions treatment 2 completed NCT01414231
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a treatment 3 unknown_status NCT01422603
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) treatment 1 / 2 completed NCT01716364
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome No drug interventions treatment 1 unknown_status NCT02172768
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease other 2 completed NCT02272478
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations treatment 2 / 3 unknown_status NCT02805946
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections prevention 4 completed NCT03217838
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. treatment 1 terminated NCT04106076
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia No drug interventions treatment 1 withdrawn NCT04217278
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT treatment 2 / 3 active_not_recruiting NCT01497002
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a treatment 3 completed NCT03672695
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. treatment 1 completed NCT01866839
Preventing Stem Cell Transplant Complications With a Blood Separator Machine No drug interventions treatment 1 / 2 completed NCT03291444
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS No drug interventions treatment 1 recruiting NCT00923910
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood treatment 1 / 2 completed NCT02231853
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections No drug interventions prevention 1 terminated NCT02124174
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS treatment 2 recruiting NCT00467961
Stem Cell Transplantation for Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT00339196
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS treatment 2 completed NCT06105658
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML treatment 2 recruiting NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis treatment 1 / 2 active_not_recruiting NCT00044486
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) prevention 3 completed NCT00152139
Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT01723657
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) treatment 2 completed NCT00152594
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia prevention 3 terminated NCT00962767
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission treatment 3 completed NCT00854646
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) treatment 1 completed NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit No drug interventions treatment 2 terminated NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00446303
A Phase II Study of Maintenance With Azacitidine in MDS Patients treatment 2 terminated NCT02140242
Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML treatment 3 completed NCT01756118
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia treatment 1 completed NCT00406393
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) treatment 3 completed NCT01339910
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) treatment 3 terminated NCT03796390
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia No drug interventions treatment 1 unknown_status NCT02895412
Infection and Tumour Antigen Cellular Therapy No drug interventions prevention 1 unknown_status NCT02255162
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML treatment 1 terminated NCT02244658
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia treatment 3 unknown_status NCT02177812
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) treatment 1 terminated NCT01809392
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome treatment 2 / 3 unknown_status NCT01716793
Risk-adapted Therapy for Adult Acute Myeloid Leukemia. treatment 2 completed NCT01621477
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant treatment 2 terminated NCT01462578
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) treatment 2 completed NCT01428427
Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors treatment 1 completed NCT01188798
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies treatment 3 completed NCT01167166
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) treatment 1 / 2 completed NCT01051063
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy No drug interventions treatment 1 completed NCT00725283
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) No drug interventions treatment 1 completed NCT00559091
A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia treatment 2 completed NCT00449319
AML Treatment in Untreated Adult Patients other Not Available unknown_status NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor prevention 2 terminated NCT00304447
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia treatment 4 completed NCT00286845
Use of the MiCK Assay for Apoptosis in AML No drug interventions Not Available Not Available completed NCT00251368
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia treatment 1 completed NCT00201240
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) No drug interventions treatment 2 completed NCT00186381
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission No drug interventions treatment 2 completed NCT00155844
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" No drug interventions Not Available Not Available unknown_status NCT00136084
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia treatment 3 completed NCT00126321
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) treatment 2 unknown_status NCT00067002
Randomized Double Cord Blood Transplant Study treatment 2 completed NCT00061581
Experimental Bone Marrow Transplant Protocol No drug interventions treatment 2 completed NCT00048100
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes No drug interventions treatment 1 terminated NCT00015587
Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) No drug interventions Not Available Not Available completed NCT00000589
Trial to Reduce Alloimmunization to Platelets (TRAP) No drug interventions prevention 3 completed NCT00180115
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients treatment 4 completed NCT00487448
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia treatment 4 completed NCT00504920
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients No drug interventions Not Available Not Available completed NCT04452604
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 No drug interventions Not Available Not Available completed NCT00435864
Natural Killer Index From Hematopoietic Stem Cell Graft No drug interventions health_services_research Not Available completed NCT05499611
Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia No drug interventions Not Available Not Available active_not_recruiting NCT01611116
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia treatment 2 completed NCT00354120
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant No drug interventions treatment 2 / 3 completed NCT05696457
Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT No drug interventions supportive_care Not Available completed NCT04082286
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia No drug interventions treatment 1 completed NCT03280290
Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft No drug interventions diagnostic Not Available completed NCT01966497
Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia No drug interventions Not Available Not Available unknown_status NCT01457885
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen treatment 2 completed NCT01435343
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia treatment 1 / 2 completed NCT01307241
RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML No drug interventions Not Available Not Available unknown_status NCT01296178
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years treatment Not Available recruiting NCT01041040
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) treatment 4 completed NCT00552825
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children No drug interventions Not Available Not Available completed NCT00538278
Prospective Database for Acute Myeloblastic Leukemia No drug interventions health_services_research Not Available unknown_status NCT00390715
Treatment of Acute Myeloblastic Leukemia in Younger Patients No drug interventions Not Available Not Available completed NCT00726934
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients No drug interventions supportive_care Not Available completed NCT00923234
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes treatment 1 terminated NCT01795924
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 1 / 2 terminated NCT01635296
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia treatment 1 completed NCT04989335
Bisantrene Combination for Resistant AML treatment 2 recruiting NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives treatment 2 terminated NCT02007863
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia treatment Not Available completed NCT02267863
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS treatment 1 terminated NCT01020539
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia treatment 1 completed NCT02395822
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients No drug interventions treatment 2 completed NCT00136448
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) Not Available 2 completed NCT03152526
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR No drug interventions treatment Not Available terminated NCT03214666
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies treatment 1 / 2 terminated NCT01119066
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies treatment 2 completed NCT00911066
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia treatment 1 completed NCT00334074
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS treatment 2 completed NCT00324220
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia treatment 1 / 2 completed NCT00304720
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor treatment 2 unknown_status NCT02662920
Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML) No drug interventions Not Available Not Available completed NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT02203773
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) treatment 1 terminated NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT00412360
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) treatment 3 completed NCT00529360
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL treatment 1 / 2 completed NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant treatment 2 completed NCT00299780
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. No drug interventions treatment 1 completed NCT00044889
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia treatment 2 completed NCT04172844
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia treatment 1 terminated NCT00981240
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes No drug interventions treatment 1 completed NCT01854567
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT01090167
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) treatment 1 completed NCT00116467
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia No drug interventions treatment 2 completed NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available recruiting NCT02576301
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS treatment 1 / 2 unknown_status NCT01842672
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia treatment 1 / 2 completed NCT00360672
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome treatment 2 completed NCT04278768
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 1 / 2 recruiting NCT00104468
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) treatment 1 / 2 terminated NCT00396968
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS No drug interventions treatment 1 / 2 withdrawn NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies treatment 2 completed NCT01145846
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) treatment 3 unknown_status NCT00967512
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course treatment 2 withdrawn NCT02730312
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies treatment 1 completed NCT02221310
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS treatment 2 completed NCT00414310
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) treatment 2 completed NCT00569010
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT02566395
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies treatment 3 completed NCT04530695
Diagnosis and Treatment of Periodontal Disease in Patients With AML No drug interventions treatment Not Available withdrawn NCT03761914
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers treatment 1 / 2 active_not_recruiting NCT01200355
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome treatment 4 completed NCT00074750
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) No drug interventions treatment 1 terminated NCT03679650
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients treatment 1 recruiting NCT00720850
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) treatment 2 terminated NCT01106950
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) treatment 2 terminated NCT01641250
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia treatment 1 completed NCT06175923
Role of BMP Pathway in MDS Progression Not Available Not Available not_yet_recruiting NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT01385423
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) treatment 1 completed NCT01773408
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia treatment 1 completed NCT03820908
Bisantrene for Relapsed /Refractory AML treatment 2 completed NCT00003838
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow treatment 2 completed NCT00430443
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML treatment 1 terminated NCT00892190
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome treatment 1 completed NCT00297921
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy Not Available 1 / 2 withdrawn NCT02340884
A Pilot RCT of the PRISM Intervention for AYAs With Cancer No drug interventions health_services_research 2 completed NCT04762875
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies treatment 2 terminated NCT00923442
Biology Studies of Hematologic Cancers No drug interventions Not Available Not Available enrolling_by_invitation NCT04188678
Resiliency in Older Adults Undergoing Bone Marrow Transplant No drug interventions other Not Available active_not_recruiting NCT03755414
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation treatment 1 completed NCT05974150
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring No drug interventions Not Available Not Available recruiting NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT03971799
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 recruiting NCT04904588
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide treatment 2 recruiting NCT00346632
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia No drug interventions treatment 1 terminated NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT05321940
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias No drug interventions treatment 1 withdrawn NCT03904251
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia treatment 1 terminated NCT02639559
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies treatment 2 completed NCT00106600
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) treatment 1 / 2 completed NCT00285259
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) No drug interventions treatment 2 completed NCT02117297
SCT Plus Immune Therapy in Average Risk AML/MDS treatment 2 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT04023071
FT516 in Subjects With Advanced Hematologic Malignancies treatment 1 terminated NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor treatment 2 completed NCT01096602
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission No drug interventions treatment 2 active_not_recruiting NCT03059485
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission No drug interventions treatment 2 recruiting NCT01366612
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation treatment 3 terminated NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors treatment 2 completed NCT02662933
Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML) No drug interventions supportive_care Not Available completed NCT05739409
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia No drug interventions treatment Not Available not_yet_recruiting NCT02338479
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies No drug interventions Not Available Not Available active_not_recruiting NCT02323113
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) No drug interventions treatment 1 / 2 terminated NCT05263271
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 1 recruiting NCT04806659
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia No drug interventions treatment 1 recruiting NCT04709458
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis No drug interventions treatment 1 not_yet_recruiting NCT04024241
Medium Dose of Cytarabine and Mitoxantrone Not Available Not Available unknown_status NCT04014764
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy No drug interventions Not Available Not Available completed NCT03459859
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS treatment 1 completed NCT03263936
Epigenetic Reprogramming in Relapse/Refractory AML treatment 1 completed NCT03059615
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS treatment 2 withdrawn NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT02802267
Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy treatment 2 unknown_status NCT02631252
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia treatment 1 terminated NCT02477787
Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS treatment 2 terminated NCT02458235
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation treatment 2 completed NCT02319369
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) treatment 1 terminated NCT02296242
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes treatment 1 / 2 completed NCT02287233
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia treatment 1 / 2 completed NCT02273102
Study of TCP-ATRA for Adult Patients With AML and MDS treatment 1 completed NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT02113319
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia supportive_care 2 completed NCT02109744
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients treatment 1 / 2 completed NCT02017457
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. treatment 2 completed NCT01999556
LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia No drug interventions Not Available Not Available completed NCT01830777
Brentuximab Vedotin + Re-induction Chemotherapy for AML treatment 1 completed NCT01814826
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older other 1 completed NCT01795378
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation treatment 1 / 2 completed NCT01779843
Alisertib for Acute Myeloid Leukemia treatment 1 completed NCT01749111
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis prevention 3 terminated NCT01745913
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies treatment 2 terminated NCT01744223
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT01736943
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia treatment 2 completed NCT01681537
Lenalidomide Plus Chemotherapy for AML treatment 1 completed NCT01639456
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission treatment 2 withdrawn NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT01611298
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR prevention Not Available completed NCT01597778
Double Cord Versus Haploidentical (BMT CTN 1101) No drug interventions treatment 3 completed NCT01586455
Human Placental-Derived Stem Cell Transplantation No drug interventions treatment 1 completed NCT01556477
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). treatment 2 unknown_status NCT01537159
MRI Assessment of Leukemia Response to Therapy No drug interventions Not Available Not Available completed NCT01513109
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT01491958
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation supportive_care 2 completed NCT01486784
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia treatment 1 / 2 terminated NCT01483274
Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation treatment 1 withdrawn NCT01464359
T-Cell Depleted Double UCB for Refractory AML treatment 2 terminated NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantation treatment 2 completed NCT01397799
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) treatment 1 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT01338987
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation treatment 2 completed NCT01326728
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions Not Available Not Available terminated NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT01289678
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia treatment 2 terminated NCT01288222
Selecting a Favorable KIR Donor in Unrelated HCT for AML No drug interventions treatment Not Available completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT01207076
AHN-12 Biodistribution in Advanced Leukemia No drug interventions treatment 1 terminated NCT01193400
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years treatment 2 terminated NCT01187810
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL treatment 1 terminated NCT01160354
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) treatment 1 / 2 terminated NCT01158885
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia treatment 2 terminated NCT01149915
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias treatment 1 completed NCT01146262
Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM) No drug interventions treatment 1 / 2 unknown_status NCT01120457
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers treatment 1 completed NCT01110473
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies treatment 1 completed NCT01085656
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS treatment 1 terminated NCT01037556
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia No drug interventions treatment 1 / 2 unknown_status NCT01031498
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting supportive_care 2 completed NCT00995332
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine treatment 1 / 2 completed NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT00968071
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome treatment 2 completed NCT00954941
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis treatment 2 completed NCT00943943
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations treatment 1 completed NCT00907517
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) treatment 1 terminated NCT00882102
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) treatment 2 completed NCT00880269
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) treatment 2 completed NCT00875693
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) No drug interventions treatment 1 completed NCT00830518
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome treatment 2 completed NCT00789256
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS treatment Not Available completed NCT00760084
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT00719836
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies treatment 1 / 2 completed NCT00686543
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) prevention 4 completed NCT00656448
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS supportive_care 3 completed NCT00623935
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia treatment 2 completed NCT00619879
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies No drug interventions treatment 3 unknown_status NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD treatment Not Available terminated NCT00579111
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) treatment 1 / 2 terminated NCT00516152
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT treatment 2 completed NCT00510133
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) No drug interventions treatment 2 completed NCT00495287
A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) treatment 3 completed NCT00486265
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) No drug interventions treatment 1 terminated NCT00474006
High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML treatment 3 completed NCT00459524
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions Not Available Not Available completed NCT00443300
Effectiveness of Protected Environment Rooms for AML and MDS No drug interventions Not Available Not Available terminated NCT00418951
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections prevention 2 completed NCT00400673
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia No drug interventions treatment 2 completed NCT00398983
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) treatment 2 / 3 completed NCT00382954
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML treatment 1 completed NCT00382590
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients treatment 2 completed NCT00378534
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants treatment 2 completed NCT00374933
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation No drug interventions treatment 1 completed NCT00374296
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease treatment 2 terminated NCT00326170
Phase II 5-Azacytidine Plus VPA Plus ATRA treatment 2 completed NCT00321581
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia treatment 1 completed NCT00317642
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) treatment 3 completed NCT00315705
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. treatment 1 / 2 completed NCT00303667
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT00274248
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia treatment 1 completed NCT00270881
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies treatment 1 / 2 completed NCT00184054
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia treatment 2 terminated NCT00175812
Differentiation Induction in Acute Myelogenous Leukemia treatment 1 / 2 completed NCT00144677
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation prevention 2 completed NCT00136422
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia No drug interventions prevention 1 completed NCT00136461
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00130702
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia treatment 2 completed NCT00098033
Investigation of Clofarabine in Acute Leukemias treatment 2 completed NCT00088231
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP treatment 1 / 2 completed NCT00074737
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML treatment 2 completed NCT00064584
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) treatment 1 completed NCT00044733
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant Not Available 2 completed NCT00043810
Study of Gelonin Purging of Autologous Stem Cells for Transplantation treatment 1 / 2 terminated NCT00038870
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes No drug interventions treatment Not Available withdrawn NCT00038831
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS treatment 1 / 2 completed NCT03290664
CD3-/CD19- vs CD3-/CD56+ Haplo NK for AML Pts Who Failed 1-2 Inductions No drug interventions treatment 2 terminated NCT00475384
Haploidentical Transplantation in Patients With Acute Leukemia and Myelodysplasia treatment 1 completed NCT01575691
Phase I 5-Azacytidine Plus VPA Plus ATRA treatment 1 completed NCT01413880
Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML) treatment 2 active_not_recruiting NCT04079296
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 / 2 completed NCT00566696
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies treatment 2 completed NCT02752035
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy treatment 3 active_not_recruiting NCT06143839
VYxeoS Liposomal Italian Observational Study iN the Real Practice Not Available Not Available recruiting NCT02421939
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation treatment 3 active_not_recruiting NCT01147939
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) treatment 3 completed NCT04509622
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) treatment 3 completed NCT04702425
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) treatment 1 terminated NCT05586074
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML treatment 3 recruiting NCT06268574
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML treatment 2 recruiting NCT04102020
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy treatment 3 active_not_recruiting NCT06387420
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia treatment 1 / 2 not_yet_recruiting NCT03969420
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy treatment 2 terminated NCT01810120
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT No drug interventions treatment 1 / 2 completed NCT01629082
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia treatment 1 completed NCT02113982
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia treatment 1 / 2 completed NCT02198482
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) treatment 2 terminated NCT02134782
Yoga Fatigue Study No drug interventions supportive_care Not Available terminated NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignancies treatment 1 / 2 completed NCT05519527
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis No drug interventions treatment 1 withdrawn NCT03709576
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML treatment 2 terminated NCT04824794
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies treatment 1 / 2 recruiting NCT02927262
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission treatment 2 completed NCT05442580
CART-38 in Adult AML and MM Patients treatment 1 recruiting NCT03123029
Expanded Access to Venetoclax Not Available Not Available available NCT00890929
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT00363467
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation other Not Available terminated NCT04603001
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations treatment 1 active_not_recruiting NCT03730012
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT05697510
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM treatment 1 recruiting NCT03409081
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Not Available Not Available no_longer_available NCT03723681
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) treatment 1 completed NCT00655395
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine treatment 1 / 2 terminated NCT04716114
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated treatment 3 recruiting NCT01442714
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS treatment 2 terminated NCT02993523
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy treatment 3 active_not_recruiting NCT00185523
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) No drug interventions Not Available Not Available terminated NCT04826523
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available recruiting NCT00186823
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT02749708
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome No drug interventions treatment 1 terminated NCT01929408
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients No drug interventions Not Available Not Available completed NCT02927938
Leukemia Stem Cell Detection in Acute Myeloid Leukemia treatment 3 terminated NCT03204838
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients No drug interventions Not Available Not Available unknown_status NCT05833438
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy No drug interventions treatment 2 recruiting NCT05144243
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China treatment 4 active_not_recruiting NCT04202003
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 1 / 2 completed NCT04272203
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers No drug interventions treatment 1 terminated NCT02649790
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications treatment 1 / 2 active_not_recruiting NCT00834002
Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission No drug interventions treatment 1 completed NCT02269579
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment No drug interventions treatment 2 withdrawn NCT04266795
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy treatment 2 active_not_recruiting NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 not_yet_recruiting NCT03849651
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies treatment 2 active_not_recruiting NCT04240002
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 recruiting NCT06565975
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France Not Available Not Available active_not_recruiting NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT06550713
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies treatment 1 recruiting NCT02416388
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR treatment 2 / 3 recruiting NCT02790515
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation treatment 2 recruiting NCT05520567
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT04161885
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) treatment 3 active_not_recruiting NCT02626715
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS treatment 2 completed NCT03198234
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders No drug interventions treatment 1 terminated NCT03069352
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy treatment 3 active_not_recruiting NCT05092451
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances treatment 1 / 2 recruiting NCT06181734
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC Not Available Not Available recruiting NCT05756777
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) treatment 1 recruiting NCT03940352
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) treatment 1 active_not_recruiting NCT04813263
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT04230265
Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies treatment 1 recruiting NCT01252485
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project No drug interventions Not Available Not Available recruiting NCT05682170
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) treatment 1 / 2 recruiting NCT03188874
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) No drug interventions Not Available Not Available recruiting NCT04872595
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant treatment 2 active_not_recruiting NCT04029688
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors treatment 1 / 2 active_not_recruiting NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors treatment 2 terminated NCT04912063
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome treatment 1 terminated NCT02013648
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) treatment 3 completed NCT03922100
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML No drug interventions treatment 1 / 2 recruiting NCT03613532
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN treatment 1 recruiting NCT04081753
Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy No drug interventions diagnostic Not Available completed NCT04777916
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) No drug interventions Not Available Not Available recruiting NCT04284228
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT No drug interventions treatment 1 / 2 active_not_recruiting NCT05188170
Niclosamide in Pediatric Patients With Relapsed and Refractory AML treatment 1 recruiting NCT05907057
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. treatment 3 recruiting NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases treatment Not Available recruiting NCT05048498
Pharmacokinetics, Tolerability and Safety of NEX-18a treatment 1 completed NCT04275518
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. treatment 1 recruiting NCT03512197
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) treatment 3 completed NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT03236857
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies treatment 1 completed NCT04639024
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN treatment 2 terminated NCT04547062
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) treatment 1 completed NCT04908852
Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML No drug interventions Not Available Not Available completed NCT02781883
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML treatment 2 recruiting NCT03941964
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy treatment 3 completed NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT01191957
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML treatment 3 completed NCT04253314
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation No drug interventions Not Available Not Available completed NCT05513612
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies treatment 1 withdrawn NCT02172872
"InDACtion" vs "3+7" Induction in AML treatment 3 active_not_recruiting NCT02088541
Selinexor (KPT-330) in Older Patients With Relapsed AML treatment 2 completed NCT05488613
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) Not Available Not Available completed NCT05291390
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) treatment 2 recruiting NCT04886206
Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions treatment 1 recruiting NCT04446741
Molecular Diagnostic Platform for AML No drug interventions Not Available Not Available recruiting NCT04429191
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation treatment 1 recruiting NCT04402723
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML treatment 1 terminated NCT04395092
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) No drug interventions treatment 2 withdrawn NCT03699384
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) treatment 1 / 2 withdrawn NCT03625505
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 completed NCT03441555
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 completed NCT03360006
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer treatment 1 terminated NCT03125876
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) treatment 1 terminated NCT03071276
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia treatment 2 terminated NCT03070093
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Not Available Not Available approved_for_marketing NCT03047083
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review No drug interventions Not Available Not Available completed NCT02992860
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY treatment 2 terminated NCT02826642
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia No drug interventions treatment 1 withdrawn NCT02648932
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients No drug interventions treatment 2 terminated NCT02532010
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML prevention 2 terminated NCT02519712
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors No drug interventions treatment Not Available terminated NCT02492737
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation treatment 1 completed NCT02433483
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients treatment 2 terminated NCT02391480
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer treatment 1 completed NCT02351037
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia treatment 2 terminated NCT02259348
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation treatment 2 terminated NCT02252107
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 treatment 2 completed NCT02238925
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients No drug interventions treatment 2 completed NCT02212561
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT02204020
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS treatment 2 withdrawn NCT02181660
Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT02071927
Study of the Glutaminase Inhibitor CB-839 in Leukemia treatment 1 completed NCT01999413
Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients treatment 2 completed NCT01816230
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM treatment 1 / 2 completed NCT01772953
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT treatment 2 completed NCT01685619
AML-MDS Novel Prognostic Tests Clinical Study No drug interventions Not Available Not Available completed NCT01613976
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients treatment 1 completed NCT01520805
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome treatment 2 withdrawn NCT01463410
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler No drug interventions Not Available Not Available terminated NCT01373515
Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia other 1 / 2 completed NCT01242774
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) treatment 1 completed NCT01237808
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation treatment 3 completed NCT01180322
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine treatment 2 completed NCT01034592
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia treatment 1 terminated NCT00893373
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age treatment 2 completed NCT00850382
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT00710528
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT00666497
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) treatment 2 terminated NCT00664677
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia treatment 1 terminated NCT00656617
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) treatment 2 completed NCT00606723
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML No drug interventions treatment 3 completed NCT00568633
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML treatment 3 terminated NCT00488592
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers treatment 2 completed NCT00433745
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy No drug interventions treatment 2 completed NCT00401739
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia No drug interventions treatment 1 completed NCT00145613
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies No drug interventions treatment 2 completed NCT00093600
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT00071006
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01326377
ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS) treatment 2 completed NCT01592266
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML) No drug interventions Not Available Not Available unknown_status NCT02333058
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies treatment 2 completed NCT06226571
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias treatment 1 recruiting NCT01220544
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells treatment 1 / 2 unknown_status NCT03723135
Expanded Access for CC-486 Not Available Not Available approved_for_marketing NCT06545682
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) treatment 1 / 2 not_yet_recruiting NCT02086773
Red Cell Transfusion Goals in Patients With Acute Leukemias No drug interventions supportive_care 1 completed NCT00779480
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002) No drug interventions treatment 1 terminated NCT03412292
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) treatment 1 unknown_status NCT03260101
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study No drug interventions Not Available Not Available unknown_status NCT00088543
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant Not Available Not Available completed NCT01113502
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) treatment 1 / 2 terminated NCT06548230
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) treatment 1 / 2 not_yet_recruiting NCT02061800
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT01995578
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse treatment 2 completed NCT05884333
Cord Blood Transplant in Adults With Blood Cancers No drug interventions treatment 2 recruiting NCT02143830
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy treatment 2 recruiting NCT02989844
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT treatment 2 completed NCT02730299
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS treatment 3 active_not_recruiting NCT03600909
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia treatment 2 terminated NCT02793544
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide treatment 2 completed NCT02240537
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer treatment 1 unknown_status NCT02226861
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation prevention 1 completed NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs treatment 2 terminated NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT treatment 1 / 2 completed NCT01873495
Omacetaxine for Consolidation and Maintenance treatment 2 terminated NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT01527838
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit No drug interventions treatment 1 completed NCT01451437
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) No drug interventions treatment 1 terminated NCT01265199
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) treatment 1 terminated NCT01221857
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies treatment 1 / 2 completed NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells treatment 1 / 2 terminated NCT00943553
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects treatment 2 withdrawn NCT00672152
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation No drug interventions treatment 1 terminated NCT00528983
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia treatment 1 completed NCT03547258
Italian Non-Interventional Study of FLT3 Mutated AML Patients No drug interventions Not Available Not Available unknown_status NCT01449058
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors treatment 1 completed NCT02193958
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies treatment 1 / 2 completed NCT06047886
CD34 Selection Using the Automated CliniMACS Prodigy No drug interventions treatment 1 not_yet_recruiting NCT02888522
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML No drug interventions Not Available Not Available unknown_status NCT02606825
VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years No drug interventions Not Available Not Available completed NCT06499025
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) treatment 0 recruiting NCT00863148
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT00652626
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function other 1 completed NCT05153226
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG prevention 3 recruiting NCT02039726
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive treatment 3 completed NCT03118466
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia treatment 2 completed NCT01188174
Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure treatment 2 completed NCT00589082
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML treatment 3 completed NCT04686682
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors No drug interventions treatment 1 / 2 recruiting NCT00820976
Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML treatment 3 completed NCT03031262
Efficacy and Safety of Chidamide in CBF Leukemia treatment 1 / 2 unknown_status NCT05290662
Registry of Patients Having Received oNKord® Not Available Not Available recruiting NCT00167180
Post Transplant Donor Lymphocyte Infusion treatment 2 terminated NCT05239689
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies No drug interventions treatment 0 recruiting NCT01012492
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT treatment 2 completed NCT00891592
Umbilical Cord Blood Transplant for Hematological Malignancies No drug interventions treatment 1 completed NCT04766840
Donor-derived CAR-T Cells in the Treatment of AML Patients No drug interventions treatment 1 unknown_status NCT05339204
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission No drug interventions treatment Not Available recruiting NCT05252572
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies No drug interventions treatment 0 recruiting NCT05287568
CC-486 and Venetoclax for Acute Myeloid Leukemia treatment 1 recruiting NCT03050268
Familial Investigations of Childhood Cancer Predisposition No drug interventions Not Available Not Available recruiting NCT00815568
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) treatment 2 unknown_status NCT05473910
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation No drug interventions treatment 1 recruiting NCT04425655
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. treatment 2 terminated NCT05226455
Venetoclax in Patients With MDS or AML in Relapse After AHSCT treatment 1 / 2 recruiting NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT05063123
Study to Assess an Interphase Cycle With Flotetuzumab. treatment 2 withdrawn NCT00707408
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) treatment 2 completed NCT04079738
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib treatment 1 / 2 terminated NCT00405743
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies treatment 1 / 2 completed NCT00333190
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation No drug interventions prevention Not Available completed NCT01319864
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients treatment 1 completed NCT01204164
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies treatment 1 completed NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant No drug interventions treatment 2 recruiting NCT06156579
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML treatment 2 recruiting NCT04365179
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML treatment 1 recruiting NCT02261779
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible treatment 1 / 2 unknown_status NCT04644016
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders treatment 2 recruiting NCT06561880
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation treatment 1 / 2 not_yet_recruiting NCT06529250
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML treatment Not Available recruiting NCT06265545
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia treatment Not Available recruiting NCT03275636
Haploidentical Donor vs mMUD in Hematological Malignancies No drug interventions treatment 2 / 3 completed NCT04857645
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients No drug interventions treatment 2 active_not_recruiting NCT06469047
Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT05184842
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML treatment 2 recruiting NCT05732688
Drug-screening in AML at Relapse for Targeted Treatment No drug interventions screening Not Available completed NCT05285813
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure treatment 2 recruiting NCT06399315
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers treatment 1 recruiting NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies treatment 1 recruiting NCT03315299
Individual Patient Expanded Access Gilteritinib (ASP2215) Not Available Not Available no_longer_available NCT02152956
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) treatment 1 / 2 terminated NCT04017546
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS treatment 1 completed NCT06211452
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia No drug interventions treatment 3 completed NCT04985357
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs No drug interventions Not Available Not Available not_yet_recruiting NCT05199051
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML treatment 2 recruiting NCT03021330
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML treatment 3 recruiting NCT04061239
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML treatment 2 recruiting NCT04443751
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) No drug interventions treatment 1 completed NCT00687414
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders No drug interventions Not Available Not Available completed NCT02575963
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients treatment 1 / 2 completed NCT05875649
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure No drug interventions Not Available Not Available not_yet_recruiting NCT05256277
NK Cell Therapy for AML No drug interventions treatment 1 terminated NCT05736978
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results treatment 2 recruiting NCT00744081
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) treatment 2 completed NCT05734898
NKG2D CAR-NK & r/rAML No drug interventions treatment Not Available recruiting NCT05740917
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS No drug interventions treatment 1 not_yet_recruiting NCT05048615
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML treatment 2 completed NCT03585517
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) No drug interventions treatment 1 completed NCT05473221
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML No drug interventions treatment 1 not_yet_recruiting NCT05467254
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML No drug interventions treatment 1 not_yet_recruiting NCT05467202
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML No drug interventions treatment 1 not_yet_recruiting NCT05463640
Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML No drug interventions treatment 1 not_yet_recruiting NCT05388305
Universal CAR-γδT Cell Injection in the AML Patients No drug interventions treatment Not Available recruiting NCT05175508
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS treatment 2 / 3 recruiting NCT05062278
Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis treatment 2 recruiting NCT04973618
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML treatment 1 withdrawn NCT04796441
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation No drug interventions treatment Not Available recruiting NCT04599452
NK Cell Therapy Recurrent/Refractory Elderly AML No drug interventions treatment 1 / 2 not_yet_recruiting NCT04187495
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) treatment 1 recruiting NCT04128020
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia treatment 1 withdrawn NCT03855371
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS treatment 1 recruiting NCT03647800
Study of APVO436 in Patients With AML or MDS treatment 1 recruiting NCT03622541
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD treatment 2 completed NCT03491579
Epacadostat, Cladribine and Cytarabine (ECC) in AML treatment 1 withdrawn NCT03466320
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 treatment 1 / 2 completed NCT03444649
Epacadostat, Idarubicin and Cytarabine (EIC) in AML treatment 1 withdrawn NCT03170895
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD treatment 2 completed NCT03138395
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML No drug interventions Not Available Not Available withdrawn NCT03135054
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD treatment 2 unknown_status NCT03031249
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia treatment 1 / 2 unknown_status NCT03021395
Efficacy of Decitabine in Clearance of MRD treatment 1 / 2 suspended NCT02905994
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia treatment 1 withdrawn NCT02886559
Chidamide Plus DCAG for Relapsed/Refractory AML treatment 1 / 2 unknown_status NCT02795520
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia No drug interventions treatment 1 / 2 terminated NCT02662647
Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML treatment 2 completed NCT02631993
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia No drug interventions Not Available Not Available completed NCT02607059
Epidemiologic Registry PETHEMA LMA 2015 No drug interventions Not Available Not Available recruiting NCT02418000
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations treatment 1 / 2 terminated NCT02221505
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT02160600
Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial No drug interventions diagnostic Not Available completed NCT02006004
Epidemiologic Registry PETHEMA LMA 2013 No drug interventions Not Available Not Available completed NCT01690507
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） treatment 1 / 2 completed NCT01570465
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients No drug interventions Not Available Not Available terminated NCT01535456
FLT-PET Imaging for MDS No drug interventions diagnostic Not Available terminated NCT01268800
Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy No drug interventions Not Available Not Available unknown_status NCT01261312
SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) other 1 / 2 completed NCT01198054
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) treatment 4 terminated NCT01192945
Non-interventional Study With Azacitidin (Vidaza®) No drug interventions Not Available Not Available completed NCT01184898
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) treatment Not Available completed NCT01074086
Phase I Study in RAD 001 Patients With Relapse AML treatment 1 completed NCT01019317
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) treatment 2 completed NCT00887068
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) treatment 3 completed NCT00858572
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders treatment 1 completed NCT00808080
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML) No drug interventions treatment 1 / 2 terminated NCT00780104
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias treatment 1 completed NCT00761449
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 treatment 2 completed NCT00700544
Treatment Outcome in Elderly Patients treatment 3 completed NCT00684918
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) treatment 2 completed NCT00684008
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant treatment 1 completed NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders treatment 2 completed NCT00533078
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies No drug interventions prevention 2 completed NCT00511537
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders No drug interventions Not Available Not Available completed NCT00176839
Stem Cell Transplantation for Hematological Malignancies treatment 2 / 3 terminated NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT00167167
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia No drug interventions treatment Not Available completed NCT00013533
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies No drug interventions treatment 0 completed NCT00246649
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia No drug interventions treatment Not Available completed NCT01488565
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia treatment 2 completed NCT04326764
Panobinostat Maintenance After HSCT fo High-risk AML and MDS treatment 3 terminated NCT05534620
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics other 1 recruiting NCT02979366
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome treatment 1 completed NCT02920541
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome treatment 1 completed NCT02550535
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients No drug interventions treatment 1 / 2 completed